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Abstract 
 
 
 Bismuth based nanomaterials have recently attracted attention as heavy 
element X-ray contrast agents because of the high atomic number and predicted 
biological compatibility of bismuth. Nanoparticle X-ray contrast agents may 
enable a number of novel medical imaging applications, including blood pool and 
site-directed imaging. However these hypothetical applications are hindered by 
lack of suitable synthetic methods for production of imaging agents. This 
dissertation describes synthesis of a novel class of bismuth nanoparticles that 
are aqueously stabilized using poly and monosaccharides. These particles are 
synthesized using highly biologically compatible reagents and are oxidatively 
stable in water and in moderately basic buffered solutions. Bismuth nanoparticles 
stabilized by the polysaccharide dextran have a large hydrodynamic radius and a 
relatively small bismuth nanocrystal core (4% bismuth by volume.) Glucose-
capped particles have a much higher ratio of bismuth by volume (>60%), and 
experimental CT scans of these particle solutions demonstrate higher X-ray 
contrast versus a current clinically used radiocontrast agent. Additional syntheses 
of hydrophobic organoamine-capped bismuth nanoparticles by reduction of an 
iodobismuth cluster, and development of other X-ray contrast materials, such as 
a radiopaque surgical sponge marker and ink, using bismuth micoparticles 
produced by a top-down ball milling method, are also described.  
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Chapter 1 – Introduction and Background to Medical X-ray Imaging and 
Bismuth as an Inorganic X-ray Contrast Material  
 
1.1 X-ray Radiography and Medical X-ray Contrast Agents 
Since the discovery of X-rays (electromagnetic radiation with wavelengths 
between 0.01 and 10 nm) in 1895 by Wilhelm Röntgen and their immediate 
application to medicine, X-ray radiography has become an indispensible method 
for noninvasive imaging of internal anatomical structures.(1) X-ray imaging is the 
most common internal anatomical structure imaging technique used in hospitals, 
and upwards of 300 million radiological exams are performed per year in the 
United States.(2) An X-ray radiograph is produced by a short exposure of X-ray 
radiation to a patient, where the partially attenuated radiation is captured on film 
or on a detector. Dense structures, most notably the calcium-based skeletal 
system, are more likely to attenuate an X-ray photon, relative to lighter, less 
dense structures, such as soft tissue.  
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A
 
B
 
 C 
 
Figure 1.1 Medical X-ray images. A.) First medical X-ray taken by 
Wilhelm Röntgen in 1895. Note that gold ring (Z=79, density= 
19.30g/cm3) is much more highly attenuating than the soft tissue of the 
hand and the calcium-based endoskeleton.(1) B.) Barium sulfate contrast 
medium used to image intestinal structures. The insoluble salt is orally or 
rectally administered and coats the intestines.(3) C.) Iodinated contrast 
medium is injected into a vein, usually in the arm, during an intravenous 
pyelogram. The radiologist takes a series of snapshots as the medium 
circulates in the blood and reaches the kidneys. Functional information is 
captured as contrast medium is filtered from the blood and passes to the 
ureters.(4) 
 
The ability of a material to attenuate X-rays is dependent on the 
attenuation coefficient of the material, which is discussed in detail later. Briefly, 
the attenuation coefficient is primarily dependent on the atomic number (Z) of the 
element or elements that compose the material, and on the density of the 
material. Different tissues types, even when composed of similar elements, can 
be radiographically differentiated based on the density differences between them. 
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For example, water (density = 1 g/cm3) and fatty tissue (density = 0.91 g/cm3) 
can be distinguished and imaged by a skilled radiologist, enabling identification of 
individual organs. However, X-rays are most useful in medicine for imaging the 
endoskeleton, which is composed primarily of calcium (Z = 20), and is a primary 
component of compact bone (density = 1.85 g/cm3). The first medical X-ray 
radiograph taken was of the hand of Anna Bertha Ludwig, the wife of Wilhelm 
Röntgen (Figure 1.1 A) which clearly shows a high contrast image of her finger 
bones and a gold ring.(1) This early X-ray radiograph demonstrates the potential 
to use X-rays for imaging dense and high Z element internal structures and of the 
X-ray attenuation potential from inorganic heavy element items, namely the gold 
ring on her finger. 
High Z reagents administered as contrast agents are commonly used in 
medicine to enhance the X-ray attenuation of anatomical structures (Figure 1.1 B 
and C) and the chemical composition and pharmacokinetics of these reagentswill 
be addressed in a separate section. Relatively X-ray transparent anatomic 
features, such as the upper and lower intestine and the kidneys, can be imaged 
by X-ray radiography with administration of an appropriate contrast agent. 
Administration of insoluble suspended contrast material, either orally or rectally, 
enables imaging of individual lobes of the intestine to survey for blockages, as 
shown in Figure 1.1 B. Soluble molecular contrast materials are administered 
intra-arterial or intra-catheter and are primarily filtered through the renal system 
and eliminated through the urine; they are thus are useful for imaging circulatory 
! 4!
and renal function.(5) An example X-ray radiograph from an intravenous 
pyelogram is shown in Figure 1.1 C, and the functioning kidneys, ureters and 
bladder are all clearly imaged with the administration of soluble, molecular 
contrast media.(4) 
 Modern X-ray based technologies, such as Computerized Tomography 
(CT) have allowed for higher resolution and 3-D images to be rendered, relative 
to 2-D X-ray radiographs. CT scanning technology was introduced in the 1970s. 
This technique scans the patient using a moving X-ray source coupled with 
moving detectors. Attenuated radiation information collected over a range of 
positions is sent to a computer that re-constructs a multilayered image of the 
internal structures of the patient. Allan M. Cormack and Godfrey N. Hounsfeld 
were awarded the Nobel Price in Physiology or Medicine in 1979 for the 
“development of computer assisted tomography”(6) and today roughly 80 million 
CT scans are performed each year in the United States.(7)  
 
1.2 X-ray Attenuation Principles 
The X-ray attenuation of a material is dependent on its X-ray attenuation 
coefficient, µ, that is defined as 
μ = ρZ4/AE3 
 where ρ is the density of the material, Z is atomic number, A is atomic mass of 
its elemental constituents, and E is incident X-ray energy. The X-ray attenuation 
coefficient is calculated from the sum of radiation scattering through a material 
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from Rayleigh scattering, Compton scattering and the photoelectron effect. 
Because the µ is an extensive property, the X-ray attenuation from atoms or 
materials is additive over a distance, and if the atomic composition is known for a 
material, the attenuation of the material can be derived by addition of the 
attenuations from the individual elemental components. µ is used to calculate the 
fraction of attenuated radiation through a given material according to the 
following equation: 
I/I0 = e[-(µ/ρ)x] 
Where I is the intensity of transmitted radiation, Io is the incident radiation 
intensity, µ is the X-ray attenuation, ρ  is the density, and x is the thickness of the 
material (cm).(8) Thus 1-(I/Io) is the fraction of radiation that is that is attenuated 
by the material as a function of the thickness. The mass attenuation coefficient 
(µ/ρ ) is a useful term for comparing the X-ray attenuations of given elements or 
materials as a function of weight. Additionally, comparing the X-ray attenuation of 
elements or materials by volume can be achieved by calculating x, which is the 
linear distance the X-ray radiation will pass through the material, from the total 
volume of the material.  
 Notably from the X-ray attenuation equation, the fraction of attenuated 
radiation is exponentially dependent on the atomic number of the atoms in the 
material, since µ is proportional to Z4. Thus the calculated µ value is inherently 
dominated by the Z term. Z values for non-radioactive elements range from 1-83, 
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and the higher Z values, such as for gold, lead and bismuth, will have a more 
dramatic exponential effect on the X-ray attenuation.  
 
Figure 1.2. Mass attenuation coefficients as a function of incident radiation 
energy for a variety of materials. Data graphed from reference (8). Notably gold, 
lead, and bismuth have similar mass attenuation coefficients. 
 
A graph of the mass attenuation coefficients (µ/ρ ) for elements and 
materials relevant to this thesis, as a function of medically diagnostic incident X-
ray energy (in keV), is shown in Figure 1.2. Bismuth, lead and gold have similar 
mass attenuation coefficients, primarily because their Z values are similar (Z= 83, 
82 and 79, respectively), but have inversely proportional densities (ρ ) relative to 
their Z values (density = 9.75, 11.35, and 19.32 respectively). Barium and iodine 
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(Z= 56 and 53, respectively) have similar atomic numbers and thus similar mass 
attenuation coefficients relative to each other.  
The K-edge energies, which are a function of the photon binding energies 
of the K-shell electrons in these elements, are evident in the mass attenuation 
coefficient vs. X-ray energy graphs as dramatic increases in X-ray attenuation at 
radiation energies just above this binding energy. The K-edge energies for the 
elements described in this section are spread out over the medically diagnostic 
imaging X-ray imaging range, which are 37.4 keV for barium, 33.2 keV for iodine, 
80.7 keV for gold, 88.0 keV for lead, and 90.5 keV for bismuth.(8) At X-ray 
energies above an element’s K-edge energy, the increased X-ray attenuation 
coefficient leads to a markedly increased X-ray attenuation. Consequently barium 
and iodine, despite their lower Z values relative to gold, lead and bismuth, have 
higher mass attenuation coefficients between roughly 40-80 keV. However, 
because the mass attenuation coefficient is correlating the X-ray attenuation as a 
function of mass, the substantially higher density of gold, bismuth and lead, 
particularly in their elemental form relative molecular or ionized iodine and 
barium, does not make iodine and barium superior contrast materials in this 
energy range by volume.  
The increase in X-ray attenuation at energies above the K-edge for 
various materials is commonly taken into account by the radiologist to optimize 
contrast, particularly when contrast materials are administered and used to image 
specific anatomical structures. The subtraction of X-ray attenuation information 
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acquired for a particular element immediately above and below it’s K-edge 
energy is an emerging imaging technique to computationally produce “color” X-
ray radiographs, or reconstructed images by detecting specific elements based 
on this dramatic change in X-ray attenuation just above a characteristic voltage. 
Color CT scanners are expected to be on the market in the next decade, and will 
be medically useful primarily in conjunction with contrast materials that have K-
edges which are distinct from surrounding materials.(9) 
 The K-edges for gold, lead and bismuth occur at X-ray energies commonly 
used for chest and pelvis radiographs. CT scans are typically performed 
substantially above these K-edge energies, commonly at 150 keV, but also at 
120 keV.(7) Subsequently, medical X-ray imaging techniques using gold, lead or 
bismuth contrast materials will prove useful X-ray contrast materials when the X-
ray energy used is above these K-edges, but will show less dramatic X-ray 
attenuation properties below the K-edges. The location of the K-edge energies 
for the specific contrast materials is useful information for radiologists who need 
to adjust imaging parameters to optimize contrast in radiographs.  
 The physical properties of the elements described in these sections will be 
important for development of novel X-ray contrast materials. Particularly the 
location of the K-edge energies relative to diagnostic X-ray energies used in 
particular medical applications is important for material optimization. Gold, 
bismuth, and lead have similarly high Z values, but different densities. These 
density differences will an affect on the X-ray attenuation by volume, but not by 
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weight of the contrast material. Thus the specific application or medical technique 
will need to be considered when selecting the elemental composition of an X-ray 
contrast material.  
 
1.3 Medical X-ray Contrast Agents 
X-ray contrast agents (XCA) are atoms, molecules or compounds, that are 
introduced internally to a patient for the purposes of imaging structures or tissue 
types that are largely X-ray transparent, typically by increasing the X-ray 
attenuation. Currently used clinical XCA include barium sulfate (BaSO4) for 
gastrointestinal (GI) imaging and small organic molecules with iodine substituents 
for imaging circulatory and renal systems. BaSO4 is a water insoluble salt, which 
is administered orally or rectally to a patient, and the white chalky suspension 
coats the patient’s GI tract rendering it X-ray opaque (Figure 1.1 B).(3) While 
ionic barium is fairly toxic, the insolubility of barium sulfate limits biological 
availability and thus this contrast material generally passes through a patient’s GI 
tract with no adverse consequences.(10)  
Iodine based XCA are water soluble molecules that can be injected into a 
patient’s circulatory system to provide increased X-ray opacity to either the renal 
system (Figure 1.1 C) or to other circulatory structures, including direct intra-
arterial injection for cardiac imaging. All iodine based contrast agents are 
variations of a 1,3,5-triiodo benzene ring with additional side chains to increase 
water solubility (Figure 1.3). Medically administered solutions contain up to 
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350 mg/mL iodine in the injectable contrast media.(5, 11) Side chains can be 
ionic or non-ionic, and the water soluble units are either monomers or dimers of 
the triiodo benzene base. Chemical structures of some clinically used contrast 
agents are illustrated in Figure 1.3. Monomeric iopramidol and diatrazoic acid 
contain three iodine atoms per molecule, and dimeric molecules iodixanol and 
ioxogalallic acid each contain six iodine atoms. Trimeric molecules have also 
been synthesized and studied, however solutions of these compounds have a 
generally higher viscosity than solutions of monomeric and dimeric contrast 
molecules.(12) 
Iodine-based contrast agents are generally divided into groups of high 
osmolality and low osmolality, depending on side chain variants. Because of the 
high injection volumes (up to 35 mL) required to generate adequate contrast, the 
osmolality of the contrast material is an important consideration for the circulatory 
stability of the patient. Patients commonly experience moderate and mild 
negative medical reactions from contrast media administration, e.g. edema, and 
less commonly patients will experience serious and fatal adverse drug effects, 
such as anaphylaxis and cardiac arrest.(13, 14) Between 1978 and 1994 the 
Food and Drug Administration reported 920 deaths from an estimated 170 million 
contrast-medium enhanced radiological studies.(15) The osmolality of the 
injected solutions appear to influence differences observed in renal toxicities 
between the various contrast agents, but other factors, such as viscosity, may 
also affect contrast agent induced nephropathy.(16, 17) 
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Figure 1.3. Chemical structures of select molecular iodinated XCAs. All iodoine-
based XCAs are 1,3,5-triiodo benzene rings with side chain modifications to 
improve water solubility. Iodine-based XCAs are monomeric (iopamidol and 
diatrazic acid) or dimeric (iodixanol and ioxogalallic acid) and are further 
classified as ionic (diatrazic acid and ioxogalallic acid) or non ionic (iopamidol 
and iodixanol). 
 
 Soluble molecular iodine-based XCAs are quickly filtered by the kidneys, 
and taking advantage of this, radiologist can use this information for the 
assessment of renal function. However, rapid renal filtration results in a short 
imaging window and the large volumes of administered contrast media required 
for imaging coupled with the clearance burden on the kidneys, these molecular 
XCAs cannot be administered to renally compromised patients. Recent research 
in iodine-based XCAs has included aggregation of clinically used XCA molecules 
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into organic polymer nanoparticles in efforts to increase contrast agent circulation 
times (by avoidance of kidney filtration) and decrease negative responses to the 
administered contrast materials by decreasing osmolality of the contrast solution, 
and the filtration burden on the renal system.(18, 19) 
 
1.4 Medical Nanoparticle X-ray Contrast Agents 
Medical XCA are currently a popular research area. The theoretical 
advantages of nanoparticle XCA relative to molecular or ionic salt based XCAs, 
include: a larger signal per unit of contrast material (a factor when osmotic 
pressure is a concern), longer circulation times due to size and molecular weight, 
opportunity to tailor surfactants to minimize adverse biological response (e.g. 
functional group display and surface charge) and the potential for site directed 
imaging by the addition of biological targeting groups to the particle surface for 
site or tissue specific imaging.(20) A nanoscale XCA that is large enough to avoid 
filtration by the kidneys would increase circulation time relative to small molecule 
iodine-based molecular XCAs, which have a short imaging window. This 
increased imaging window would perhaps allow other systems or tissues to be 
imaged, decrease the necessary and sometime repeat injection volumes, and 
enable administration of XCA to patients with compromised renal function.(21, 
22) One study using cadmium selenide quantum dots, found that mouse kidneys 
were unable to filter particles larger than 6 nm from circulation, indicating that any 
imaging agent larger than this size should escape normal kidney filtration.(23) In 
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vivo experiments using gold and bismuth based nanoparticle XCAs indicate that 
the lymph system will scavenge particles too large to be filtered through the 
kidneys on a time scale of hours or days.(24) Possible alternate clearance routes 
for nanoparticle vs. molecular XCAs are a potential primary advantage of these 
novel materials, but also a potential toxicity concern, particularly when the XCA is 
composed of heavy elements not typically available biologically.(25, 26)  
A number of materials have been explored as nanoparticle XCA, including 
Bi2S3 nanoparticles wrapped in organic polymers,(27, 28) organic bismuth salts 
aggregated with polymers into nanoparticles(29, 30) gold nanoparticles 
(AuNPs)(31, 31, 32), PEGylated ytterbium oxide particles doped with erbium (33) 
and particles with a core composed of tantalum oxide.(34, 35) Studies exploring 
nanoparticle XCAs in vivo have primarily focused on AuNPs, and these reports 
have demonstrated that inorganic nanoparticle XCA have a long circulation time 
and that the particles ultimately localize in the spleen and liver.(36) The chemical 
stability of AuNPs has also enabled a number of proof-of-principal studies for site 
directed imaging.(24, 37) However the chemical stability of AuNPs has become 
their own barrier to application, as particles appear to bioaccumulate, which, 
coupled with the extremely high cost of gold, limits further development of AuNPs 
as XCAs.(38–40)  
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1.5 Introduction to Bismuth Nanoparticles as Medical X-ray Contrast 
Agents 
 
This thesis is focused on the development of novel nanoscale BiNP XCAs 
with a high density and large concentration of X-ray opaque atoms, using 
biologically compatible reagents and solvents. These high payload nanoscale 
XCAs are developed to be used as biological imaging agents, and thus a 
synthetic focus on biological compatibility is a primary concern. Because of 
recent toxicity reports for AuNPs XCAs arising from biological accumulation 
associated with the chemical stability for AuNPs, the development of BiNP XCAs 
materials may be advantageous because of a lowered chemical surface stability 
for BiNPs and known biological compatibility for bismuth(III) species.  
The ideal BiNP XCA will be between 10 and 200 nm to allow for free 
passage through the circulatory system, but avoid filtration by the kidneys.(23) 
The choice of elemental bismuth as an inorganic nanoparticle core for the 
functional atoms in an XCA, comes from the unique chemical and physical 
properties of this element. Bismuth-209 is the only natural isotope and is also the 
highest atomic number, negligibly-radioactive isotope with an alpha emission half 
life of 2x1019 years.(41) Furthermore bismuth is moderately abundant and 
inexpensive, which are relatively rare characteristics of elements of the 4th and 5th 
periods.(42) Uniquely among the high Z elements, bismuth has a long history of 
known biological tolerance and medicinal use. These properties make bismuth 
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the heaviest Z element that can be used as an XCA, that, coupled with potential 
for biological compatibility, makes bismuth ideally suited to this application. 
Bismuth’s low toxicity, coupled with its known anti-microbial properties, 
have made it commonly used in medicine for millennia.(43) For example Pepto-
Bismol is a suspension of bismuth(III) subsalicylate that has been marketed for 
over a century as an anti-emetic and general treatment for gastrointestinal 
problems. Originally, Pepto-Bismol was developed in New York as a treatment 
for children suffering from undefined intestinal illness characterized by diarrhea 
and upset stomach, and contained red food coloring to appeal to children. Today 
upwards of 60% of US households have a form of Pepto-Bismol, and it is one of 
the most commonly used over the counter medications world wide.(44) The anti-
microbial properties of bismuth(III) compounds have been demonstrated, but the 
biological mechanism responsible for this property is still poorly understood. 
Laboratory and medical research have established the role of bismuth(III)  in 
suppression of Helicorbacter pylori growth and infection rates, which has 
continued to make bismuth(III) based medicines extremely popular. Some 
evidence indicates that bismuth(III) ions prevent protein synthesis in pathogenic 
microbes, and it has also been suggested that bismuth(III) ions, precipitated as 
bismuth oxide, form a barrier in the GI tract, which physically bars microbes from 
adhesion.(45) Other studies suggest that the cationic nature of bismuth(III) ions is 
responsible for disruption of normal cell-wall forming function. New organic 
bismuth(III) drugs are currently under exploration and development. These efforts 
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have shown that the bioavailability and the biological localization of bismuth(III) 
ions is dependent on the organic ligand component, specifically on its 
hydrophilicity or hydrophobicity (modes of action for bismuth(III) compounds and 
novel bismuth(III) drugs are reviewed in references 46–52). Generally, the 
literature does not agree on the specific anti-microbial mechanism, or 
mechanisms, of bismuth(III) ions in vivo, but all agree it is one of the most 
effective treatments for H. pylori infection and eradication.  
The postulated fate of ingested bismuth(III) subsalicylate is intestinal 
decomposition into salicylic acid and bismuth oxide, bismuth carboxylate and 
bismuth oxychloride.(46) These insoluble bismuth(III) salts primarily pass through 
the GI tract without absorption, however some free bismuth(III) is found in the 
circulatory system. High plasma levels of bismuth(III) have been associated with 
encephalopathy and a “safe” bismuth(III) blood concentration of <100 µg/mL has 
been established as a clinical patient toxicity threshold. Furthermore, general 
medical opinion has established that bismuth(III) blood levels below 50 µg/mL 
are unlikely to cause any adverse health effects.(48) One study reported that an 
apparently healthy volunteer, who consumed gram scale quantities of bismuth 
subsalicylate over 30 days, reached a peak 13.6 ng/mL serum concentration with 
no adverse medical effects.(53) Another study followed patients who consumed 
tripotassium dicitrato bismuthate tablets, and found they reached a peak bismuth 
plasma concentration of 50 – 100!ng/mL.(54) Encephalopathy from prolonged 
bismuth(III) ingestion has been reported in the literature, but notably all reports 
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indicate that the symptoms are reversible and that no lasting effects have been 
reported when bismuth(III) levels return to normal (2-11 ng/L).(48, 55, 56) 
Attempts to evaluate bismuth(0) toxicity in rats determined an LD50 of 
>2,000 mg/kg for ingested 10 µm elemental bismuth powders, and no negative 
reactions were observed when amounts of 1,000 mg/kg were ingested.(57) While 
the literature is varied and inconclusive about the intravenous and ingested 
toxicity concentrations, it is noted that the toxicity is expected to be inherently 
linked to the solubility of bismuth(III) ions. It is thus likely that bismuth(0) particle 
toxicity will likely be particle size and environment dependent, and will ultimately 
be dependent on the liberation of bismuth(III) ions by in vivo oxidation.  
To use elemental BiNPs as long circulating XCAs, ideally the inorganic 
elemental BiNP will be administered to maximize X-ray opaque payload and 
allowed to freely circulate with a long half-life, before clearance or decomposition. 
Toxicity of BiNP XCAs will most likely be a function of the soluble bismuth(III) 
species evolved from the particles, free radicals evolved from the conversion of 
elemental bismuth to bismuth(III) species, and any organic component of the 
particles which are released as particles decompose. Other toxicity concerns for 
BiNP XCA will be from particle aggregation in circulation, immune responses to 
the administered materials, or surface interactions with specific tissue types or 
structures. However, these responses will be almost impossible to predict and 
will thus require empirical evidence and experimentation. The characterization of 
all components, including starting materials and the materials evolved from the 
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decomposition of particles, will be the most likely in vitro evidence to enable 
predictions of BiNP biocompatibility. Thus using known biologically compatible 
starting reagents, and avoiding reagents with known toxicities that may 
subsequently be released during BiNP decomposition, will produce the most 
potentially biocompatible XCA. 
 Syntheses of extremely high surface area nanoparticles are generally 
carried out in coordinating solvents, which makes them very difficult to purify from 
the reaction solvent. Bismuth starting materials are also challenging, as bismuth 
is insoluble in most solvents, and only in water at dilute concentrations and under 
acidic conditions. Counterions for bismuth(III) compounds are also need to be 
considered during synthesis because of their role in either particle formation, 
particle stabilization, or additional and unintended reactions. For example BiCl3 
and bismuth(III) nitrate have identical oxidation states and are both known to 
disassociate, however the chloride ion and nitrate ion may behave very differently 
in a reaction and effect the final BiNP product. Because the focus of this thesis is 
on the development of biocompatible elemental BiNPs, all reagents, starting 
materials, and the chemical composition of the resultant particles are considered. 
Particular focus is given to capping agents of BiNPs, and the oxidative 
stabilization of these particles in aqueous solutions.  
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1.6 Literature Bismuth(0) Nanoparticle Synthetic Preparations  
 The bismuth(0), bismuth(III) and bismuth(V) precursors, organic ligands, 
and polymers that published literature preparations have reported for the 
synthesis of BiNPs vary widely. Additionally, reported preparations use a variety 
of solvents, reducing agents (for bottom up synthesis), and surfactants or 
capping agents. This section will discuss previously published methods for the 
synthesis of nanoscale bismuth(0) materials and some of the implications that 
physical and chemical synthetic parameters will have on the final morphology of 
the nanomaterials. One particular detail that will not be addressed in the following 
analysis is the effect that the chain length of the common surfactant 
poly(vinylpyrroldone) (PVP) will have on nanoparticle morphology. This particular 
synthetic detail may have implications for the selective growth of bismuth(0) 
nanowires instead of bismuth(0) nanoparticles, in addition to other physical and 
chemical factors. Discussions herein will focus on the identity of the chemical 
reagents used to produce bismuth(0) nanoparticles, and how these reagents, in 
addition to some physical parameters, will direct morphology of the final 
materials.  
As nanoparticle syntheses can be generally organized into two types of 
methods (top down and bottom up), nanoparticles produced by these two 
methods will be discussed separately. Representative TEM images from prior 
literature preparations will be presented, but it should be noted that images 
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selected for publication may not be representative of the entire population of 
particles produced by these methods.  
 
1.6.1 Top-down Synthetic Methods for Production of Bismuth(0) 
Nanoparticles 
  A top down nanomaterial synthetic technique is defined as the physical 
reduction in size of a bulk material to a finer grain-sized material having at least 
one dimension on the nanoscale. For the synthesis of BiNPs, this entails 
converting bulk elemental bismuth(0) to smaller bismuth(0) particles, which offers 
the potential to produce large quantities of inexpensive particles as no additional 
reagents are required for an oxidation state change (see Chapter 5 for a detailed 
schematic of a top-down synthesis protocol). Top-down synthetic methods for 
bismuth nanomaterials are achieved either by physical fracture of the bulk 
material (grinding) or melting the bulk material and stirring in a solution with a 
surface stabilizing molecule to produce small liquid droplets that solidify on 
cooling (solution phase synthesis.) Formation of nanoparticles by a top-down 
solution phase synthesis in high boiling point organic solvents is unique to low 
melting point elements. Elemental bismuth(0) has a relatively low melting 
temperature (271 °C), and in general, nanoparticles are predicted to have a 
depressed melting temperature relative to the bulk material.  
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Figure 1.4. Representative electron microscopy images and XRD patterns from 
top down syntheses of BiNPs. Zhao et al. report a synthetic method whereby 
elemental bismuth is melted in paraffin to produce nanoparticles. The XRD 
pattern (A) contains peaks assigned to elemental bismuth () and bismuth(III) 
oxide (). A TEM image of particles shows a highly polydisperse population 
(B).(58) Wang and Xia report the synthesis of BiNPs by melting bismuth(0) 
powders in diethylene glycol and PVP. The XRD pattern (C) matches 
rhombohedral bismuth and particles are morphologically uniform and 
monodispersed when imaged by SEM (D) and TEM (D inset).(59) 
 
 Two published top-down bismuth particle syntheses will be discussed 
here. The first preparation was carried out by heating bismuth(0) granules in 
paraffin in a sealed contained for 10 hours with stirring at 280 °C to melt the bulk 
! 22!
bismuth in a contained environment.(58) The soluble bismuth particulate material 
was washed with chloroform to remove excess paraffin, and the BiNPs were 
collected. The X-ray diffraction pattern of the washed particles contains peaks 
from both rhombohedral bismuth and bismuth oxide (Bi2O3) (Figure 1.4 A) and 
the authors note that this suggests that that an oxide layer is formed on the 
surface of the particles. Shown in Figure 1.4 B are particles obtained by this 
method. Because paraffin is a hydrocarbon, it was assumed that the oxide 
formed on the particle surface is from air, or perhaps a solvent contamination. 
The adsorption of environmental oxygen is well noted for molten bismuth. The 
particles produced by this first method are heterogenous and this preparation 
appears to provide poor morphology control of the resultant material, which is 
unsurprising given the lack of surfactant included in the synthesis. 
 A second published method for top-down particle synthesis was carried 
out by melting bismuth powders (100 mesh) in diethylene glycol in the presence 
of PVP at the boiling point (241 °C) of the solvent.(59) Particles produced by this 
method were found to have 10 nm PVP coating by comparing the TEM core size 
to the SEM particle size, and XRD analysis (Figure 1.4 C) indicates an entirely 
elemental bismuth core, with no evidence of an oxide layer on the particle 
surface. This would suggest that PVP was able to effectively surface passivate 
BiNPs and prevent the formation of a bismuth(III) oxide layer on the particle 
surface. These particles are morphologically well controlled and appear highly 
monodispersed (Figure 1.4 D). The authors show that particles with a diameter 
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between 100 and 450 nm can be synthesized by changing the stirring rate during 
particle synthesis, and they suggest that during particle formation bismuth(0) in a 
liquid state in solution, and thus the stirring rate will affect the final particle size. 
The particles were rapidly cooled from the synthetic temperature to room 
temperature by the addition of cold ethanol. This rapid temperature quench is a 
technique often used in nanoparticle synthesis to prevent particle ripening, fusing 
or crystal aggregation during the temperature decrease post synthesis.  
 The use of top-down methods for nanoparticle syntheses is appealing 
because of the simplicity of the chemistry and the lack of redox chemistry 
required. For applications of highly X-ray attenuating material, where large 
quantities of small particles are desired, but the morphology and polydispersity of 
the particle population is not critical, a top-down method should be well suited. 
Discussed in Chapter 4 of this dissertation is a method for producing large 
quantities of micron scale bismuth particles by a top-down grinding method and 
their incorporation into polymers to produce X-ray opaque composite materials. 
 !
1.6.2 Bottom-up Synthetic Methods for Production of Bismuth(0) 
Nanoparticles 
 Syntheses of BiNPs by bottom up methods generally entail reduction of a 
bismuth cation (3+ or 5+) by a reducing agent, the aggregation of bismuth(0) 
atoms into nanoscale clusters, and the growth and stabilization of these clusters 
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in solution. Scheme 1.1 gives a general illustration for the synthesis of bismuth(0) 
nanoparticles from bismuth(III) ions. Commonly used bismuth(III) sources include 
BiX3 where X=F, Cl, Br or I, Bi2O3, Bi2S3, Bi(NO3)3·5H2O, Bi5O(OH)9(NO3)4 
Bi(SR)3 and Bi(OR)3, where OR is an oxygen containing organic ligand with a 
negative charge, such as an acetate or a deprotonated alcohol. The only 
bismuth(V) precursor discussed in this dissertation is NaBiO3, and the use of this 
precursor is confined to two studies. Chemical species that provide electrons to 
produce bismuth(0) from bismuth(III) and bismuth(V) vary, and include traditional 
reducing agents, such as organoboranes or hydrazine hydrate. Alternately, a 
general reducing solution environment, such as one generated by a polyol 
solvent at elevated temperature, (i.e. a polyol synthesis) can be used to produce 
bismuth(0). Organic surfactant species used to cap and stabilize nanomaterials 
also vary widely, but are generally either small molecular species (such as a 
primary organoamines, or carboxylic acids) or larger polymeric species, 
specifically PVP. By far the most commonly used surfactant is PVP, most likely 
because the amide functional group has a resonance structure that contains a 
partially negatively charged oxygen atom capable of electron donation for 
stabilization of a nanoparticle surface. Other surfactants reported are primary 
amines, [N(SiMe3)2]- and primary carboxylic acids, such as oleic acid. These 
surfactants all contain a lone pair of electrons and can act as ligands for 
coordinating to the particle surface and providing stabilization. The following sub-
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sections discuss published bottom up preparations of BiNPs, grouped generally 
by class or by reagents used. 
 
Scheme.1.1 General synthesis of BiNPs from a bismuth(III) 
precursor. A bismuth(III) cation is reduced via a reducing agent or 
in a reducing environment to form bismuth(0) atoms during the 
reduction phase. Bismuth(0) atoms then cluster to form nuclei 
(less than 1 nm in diameter) during the nucleation phase. 
Additional bismuth(0) atoms are added to these nuclei or multiple 
nuclei fuse, to form a nanoscale particle, and a polymer or small 
organic molecule surfactant then stabilizes the BiNP during the 
growth and stabilization phase.  
 !
BiNP Preparations Using Bi[N(SiMe3)2]3 Precursor 
 A number of bottom-up BiNP syntheses in apolar organic solvents have 
been reported to produce BiNPs; the best characterized and most widely applied 
of these preparations was developed by Buhro and coworkers.(60) In this 
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preparation BiCl3 is reacted with Na[N(SiMe3)2] to obtain a soluble Bi[N(SiMe3)2]3 
precursor material. The precursor, dissolved in tetrahydrofuran (THF), is heated 
under reflux with Na[N(SiMe3)2] at 180°C under an inert atmosphere. Poly(1-
hexadecene)0.67-co-(1-vinylpyrrolidinone)0.33, (hereafter referred to as “graft PVP”) 
carried in 1,3-diisopropylbenzene (DIPB) is used as a surface stabilizer. By 
adjusting the Na[N(SiMe3)2] and/or polymer to bismuth ratio, spheres, wires, rods 
or hexagonal nanoplates were synthesized with good size and morphology 
uniformity. Shown in Figure 1.5 A-D are 4 representative images of nanoscale 
bismuth materials obtained by this method. The morphological effects of varying 
reagent concentrations, from an empirically optimized synthetic preparation for 
round nanoparticles, are explored as justification for each reagent and 
concentration used. Hexagonal nanoplates (Figure 1.5 A) were obtained by 
decreasing the polymer concentration, nanowires (Figure 1.5 B) were obtained 
by decreasing the Na[N(SiMe3)2] concentration, and monodispersed spherical 
nanoparticles ranging from 3 to 30 nm (Figure 1.5 C and D) were obtained by 
carefully controlling the Bi[N(SiMe3)2]3 to Na[N(SiMe3)2] ratio (ratios of 1:2 up to 
6:1 were used), with higher concentrations of Na[N(SiMe3)2] generally producing 
smaller particles, suggesting that the Na[N(SiMe3)2] is surface stabilizing the 
BiNPs in addition to the polymer. Larger particles (40 to 115 nm) were obtained 
by increasing the Bi[N(SiMe3)2]3 concentration and decreasing the polymer and 
Na[N(SiMe3)2] concentration. The Na[N(SiMe3)2] and the graft PVP both affect 
the particle morphology, albeit these effects were tested empirically. The authors 
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provide little information on the distinct role of each chemical reagent during the 
synthesis, however the role of Na[N(SiMe3)2] in the particle formation kinetics has 
been recently explored and will be discussed below. Interestingly Buhro and co-
workers report that variation of the synthetic temperature from 160 to 210 °C 
does not appear to have a substantial influence on the size of the synthesized 
particles.  
 
Figure 1.5 Representative TEM images of bismuth nanomaterials produced from 
a bismuth(III) silylamide precursor. Buhro and coworkers report synthesis of 
nanoplates (A), wires (B), and 3-30 nm relatively monodispersed nanoparticles 
(C and D) in THF using a specialty PVP polymer surfactant and Na[N(SiMe3)2] 
(from reference 60). Yarema et al. report the synthesis of monodisperse, 11-
22 nm (E-H) bismuth(0) nanoparticles in hexadecylamine with dissolved 
Li[N(SiMe3)2]  that self organize into highly ordered superlattices (from reference 
61). 
 
A! B!
C! D!
E! F!
G! H!
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 The temperature insensitivity of the preparation reported by Buhro and co-
workers is in direct contrast with the work by Yarema et al., who noted that 
temperature is the important variable that controls nanoparticle size in their 
described synthesis, which also employed a Bi[N(SiMe3)2]3 precursor.(61) In this 
preparation hexadecylamine (HDA) serves as both solvent and surfactant, and 
no PVP is used. The bismuth precursor Bi[N(SiMe3)2]3, in addition to 
Li[N(SiMe3)2], was carried in toluene and injected into the hot HDA reaction 
solution. Particles were allowed to grow for 15 seconds, before the reaction was 
rapidly cooled to room temperature. By altering the synthetic temperature from 
100 to 140 °C, the size of particles could be controlled from 11 to 22 nm. 
Changing the duration of the reaction was shown to alter the size distribution, 
with a 15 second growth window producing the most monodisperse particles. The 
authors argued that incorporation of Li[N(SiMe3)2] in the reaction is essential for 
formation of morphology well controlled particles. Shown in Figure 1.6 are TEM 
images of two particle populations synthesized from Bi[N(SiMe3)2]3 in HDA, in the 
absence (Figure 1.6 A) and in the presence (Figure 1.6 B) of Li[N(SiMe3)2]. 
These images demonstrate the impact that the addition of Li[N(SiMe3)2] has on 
the morphology of the obtained nanoparticles, although particles were likely 
terminated predominantly by HDA solvent.  !!
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Figure 1.6 TEM images of BiNPs produced by the Yarema et al. method. 
Particles synthesized in HDA from Bi[N(SiMe3)2]3 in the absence (A), and 
presence (B), of Li[N(SiMe3)2]. From reference (61) supporting information. 
 
 Buhro and co-workers have also performed a detailed kinetic analysis of 
their reaction with a focus on the mechanism.(62) They varied the Bi[N(SiMe3)2]3 
to Na[N(SiMe3)2] ratio in the synthesis solution and removed aliquots for analysis 
over the duration of the reaction. By monitoring the sizes of the particles and the 
polydispersity of the populations at different time points during the reaction, they 
collected information about the reaction. Based on the number and size of 
particles observed in a sample information such as the time to maximum 
nucleation rate, duration of the nucleation period and the onset of Ostwald 
ripening, could be measured as a function of starting material concentration or 
other variables. Further analysis of this data included information such as a graph 
of the nucleation rate, which can be used to calculate the width of the nucleation 
function, namely the duration of the nucleation period, and relative standard 
deviation of particle sizes in the population. They showed a correlation between 
 S5 
 
 
 
Figure S1. TEM images for Bi NPs grown in the absence (A) and in the presence of of Li[N(SiMe3)2] (B). 
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the nucleation window and the relative standard deviation of particle diameters 
that was expected from classical LaMer nucleation and growth kinetics. However, 
their analysis also revealed that after the onset of nucleation, Ostwald ripening 
and perhaps aggregative growth also occurred. Using the particle growth rated 
and kinetics data as a function of Na[N(SiMe3)2] concentration, the authors 
concluded that Na[N(SiMe3)2] serves as a facilitator for Ostwald-ripening and as a 
surface stabilizer that sterically hinders particle association and fusion.  
 The use of Bi[N(SiMe3)2]3 as a bismuth source for BiNP synthesis has 
produced some of the most morphologically uniform and size monodispersed 
nanoparticles reported in the literature. However, the light, temperature and air 
sensitivity of Bi[N(SiMe3)2]3 makes these syntheses difficult and cumbersome. To 
minimize the number of steps required to synthesize BiNPs and simplify their 
synthesis method, Buhro and co-workers later reported a modified method that 
produced BiNPs directly from a BiCl3.(63) In what they term a “shortcut” 
synthesis, a specific chemical addition sequence is key to the formation of 
particles. The addition of BiCl3 to the reaction vessel, followed by dry THF, then 
the graft PVP, followed by Na[N(SiMe3)2], enabled them to produce particles 
similar in size and uniformity to the particle produced by their previously reported 
method, without first synthesizing and purifying a Bi[N(SiMe3)2]3 precursor. They 
again demonstrated a size control of the particles by adjusting the Bi[N(SiMe3)2]3 
to Na[N(SiMe3)2] ratio.  
! 31!
 A study by Schulz et al., took advantage of the high reactivity and solubility 
of Bi[N(SiMe3)2]3 and focused on the synthesis of bismuth pseudocubes (a 
nanocrystal  that appears morphologically cubic, but does not belong to the cubic 
crystal system, see Appendix A).(64) However, in this preparation they used this 
bismuth(III) source to first synthesize Bi2Et3 that was then thermally decomposed 
in THF with graft PVP, DIPB and Na[N(SiMe3)2]. The solution was stirred at 50 °C 
for 4 hours, then at 170 °C for 12 hours to precipitate bismuth(0) pseudocubes 
out of solution. As with previous synthetic studies, the addition of the polymer and 
Na[N(SiMe3)2] were observed to affect the final morphology of the nanoparticles 
produced.  Using a Bi2Et3 bismuth(III) precursor material is a novel synthesis 
choice because it is reactive enough at 50 °C to decompose and form highly 
faceted seeds that enable the growth of non-spherical BiNPs. The authors 
discussed the roles of PVP and Na[N(SiMe3)2] in controlling the morphology of 
the particles as they grew, and hypothesized that PVP should preferentially 
associate with specific bismuth(0) crystal faces to direct shape and that 
Na[N(SiMe3)2] serves to prevent aggregation of particles. However, they also 
note both the PVP and Na[N(SiMe3)2] are necessary in their synthesis to produce 
particles of a specific morphology, and thus conclude it is a kinetic rather than 
thermodynamic pathway directing particle synthesis. Given the studies by Schulz 
et al.  and the conclusions drawn by Buhro and co-workers in their 3 papers, it is 
likely PVP and Na[N(SiMe3)2] are working together to direct particle morphology, 
but the role of each reagent is unclear. 
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 All of the methods described in this section are carried out under an 
anaerobic and anhydrous reaction environment and produce particles with a 
hydrophobic ligand display. While the reaction conditions and reagents used in 
these studies are not ideal for BiNPs that are to be employed in biological 
applications, the exquisite size and morphology control and detailed analysis of 
these particle preparations is useful for understanding BiNP formation kinetics 
and surface stabilization chemistry.  
 
Bismuth Nanoparticle Thiol Syntheses 
Bismuth(III) thiolate precursors have been reported for the synthesis of 
BiNPs, and while the solubility of a bismuth(III) thiolate (Bi(SR)3)should be high in 
apolar solvents, the preferential formation of Bi2S3 over bismuth(0) limits reaction 
conditions in which this type of precursor will form bismuth(0). Warren et al. 
described a BiNP synthesis that used light to catalyze the formation bismuth(0) in 
octadecene from a bismuth(III) decanethiol precursor.(65) This synthesis is a 
relatively simple and straight-forward process, whereby the thiolate ligands are 
oxidized to dithiols generating a ligand to metal charge transfer and a reducing 
environment capable of producing bismuth(0) particles. The process takes place 
in a sealed vessel exposed to ambient light over the course of two weeks. The 
authors called this a polythiol reaction and demonstrated its applicability in the 
synthesis of other elements, such as copper, lead and antimony nanoparticles. 
This method has a number of advantages such as a low cost reducing agent (the 
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thiol), high dispersity of the metal coordinating ligand in apolar solvents that 
assists with solubility of inorganic atoms, and an ambient synthetic temperature. 
BiNPs produced by this method appear rhombohedral and form highly organized 
super-lattices when they are imaged by TEM (Figure 1.7 A).  
 
Figure 1.7 Representative TEM images of BiNPs produced from bismuth(III) 
thiolate precursors. Bismuth(III) decanethiol was suspended in octadecene and a 
light catalyzed formation of disulfide species generated bismuth(0) particles (A, 
from reference 65.) Thermal decomposition of bismuth(III) dodecanethiolate in a 
sealed container produced bismuth(0) particles at 120°C (B) or 135°C (C, from 
reference 66.) Bismuth(III) dodecanethiolate was reduced by tri-n-octylphosphine 
in octadecene to produce BiNPs of reported average sizes of 11 nm (D) 14 nm 
(E) 20 nm (F) or 27 nm (G, from reference 67.) 
 
A more recent preparation described by Chen et al.(66) also decomposed 
a bismuth(III) thiolate species to form bismuth(0) particles. In this work, 
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bismuth(III) dodecanethiolate was synthesized, purified and sealed in a Pyrex 
tube, then heated for 10 hours to form bismuth(0) nanodisks. No additional 
solvent was used in the synthesis. The authors illustrated the effect that synthetic 
temperatures have on the particle sizes, with a 120 °C synthetic temperature 
producing relatively smaller particles (Figure 1.7 B) vs. a 135 °C synthetic 
temperature (Figure 1.7 C.)  
Son et al. (67) reported a synthesis that used bismuth(III) 
dodecanethiolate reduced by tri-n-octylphosphine (TOP) in octadecene to 
produce BiNPs 6 to 17 nm in size (Figure 1.7 D-G). The temperature range (55 to 
80 °C), growth time (1.5 to 30 minutes) and the TOP concentration and injection 
temperature (20 to 70 °C) were varied to produce different sized particles. 
Because the focus of the study was on producing particles for thermoelectric 
measurements, synthetic details and mechanisms were not fully explored. 
Increasing the synthetic temperature (from 55 °C to 65 °C) produced particles 
from 6 to 11 nm, and increasing TOPO concentration and growth time (at 70 °C  
to 80 °C), in addition to increasing the temperature of the TOPO addition, 
produced particles 14  to 27 nm in size. Shown in Figure 1.7 D-G are particles 
synthesized by this method. It should be noted that small particle nuclei are 
evident in some of the TEM images (particularly in Figure 1.7 E) suggesting a 
heterogeneity that is apparently not included in the reported population 
distribution.  
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Organic-phase BiNP Syntheses Using Bismuth(III) Salts 
The use of the polar organic solvent N,N-dimethylformamide (DMF) for 
BiNP synthesis is popular, and a few of these preparations, which are generally 
performed under anaerobic conditions, will be described here. These 
preparations use commercially available bismuth(III) salts, such as BiCl3 or 
Bi(NO3)3, and NaBH4 as a reducing agent. Additionally these preparations use 
PVP as a surface stabilizer, most likely, as discussed above, because of the high 
electron density donation afforded by the amide group. Wang et al., report a 
preparations that used BiCl3 as the starting bismuth(III) source, and described 
the effect that the ratio of PVP to bismuth(III) has on the size and extent of 
aggregation of BiNPs produced by this reaction (Figure 1.8 A and B). When 
particles were synthesized with a PVP to bismuth(III) ratio of less than 1:1 (Figure 
1.8 A) the particles appeared highly aggregated. Particles synthesized with a 
PVP to bismuth(III) ratio of 5:1 are smaller and less aggregated, suggesting a 
greater separation of the nanocrystals in solution when the concentration of 
surfactant is higher (Figure 1.8 B). They further characterized these particles and 
described the formation of the PVP-bismuth bond by measuring a shift in the FT-
IR absorbance of the carbonyl group in PVP. The C=O bond in neat PVP has a 
bond absorbance at 1675 cm-1, and when associated with a bismuth(III) cation in 
solution, this bond absorbance shifts to 1588 cm-1. This can be explained by an 
increase in electron density around the oxygen atom, and consequently a 
decrease in the electron density in the C=O bond. This decrease in electron 
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density at the carbonyl double bond leads to a lower energy wavelength 
absorbance. When PVP surface stabilizes BiNPs, this absorbance wavelength 
shifts to 1659 cm-1. These observations can be explained by the formation of a 
coordinative PVP-bismuth(III) bond when the polymer is associated with the 
bismuth(III) cation. After reduction of the bismuth(III) ions, the PVP retains a 
coordinative bonding interaction with the bismuth(0) nanoparticle surface. This 
observation suggests that relative to neat PVP, the carbonyl group is mildly 
electron donating to the bismuth(0) nanoaparticle surface, and strongly electron 
donating to the bismuth(III) cation in solution. 
Interestingly DMF also contains an amide group, and while the PVP 
polymer has been demonstrated to be effective for colloidal stabilization of BiNPs 
in solution, it seems likely that some DMF also surface stabilizes and coordinates 
to the particle surfaces. Su and co-workers have worked with BiNPs produced by 
reduction of Bi(NO3)3 by NaBH4 in DMF with PVP surface stabilization (Figure 1.8 
C and D). Transfer of these particles from an organic solvent to aqueous BiNPs 
has been demonstrated, but because the synthesis was carried out in a highly 
coordinating solvent, namely DMF, it is likely that traces of the solvent are still 
present on the particle surfaces. This contamination could yield cytotoxic BiNPs 
that are unrelated to bismuth(0) toxicity.  
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Figure 1.8 BiNPs produced by NaBH4 reduction of a bismuth(III) salt in DMF in 
the presence of PVP. The ratio of bismuth(III) to PVP affects the particles size 
and extent of aggregation, as illustrated by particles synthesized using a PVP to 
bismuth(III) ratio of 0.15:1 (A) and 5:1 (B, from reference 68.) BiNPs synthesized 
with a PVP to bismuth(III) ratio of 5:1 (C and D) were phase transferred to 
aqueous solutions and used in cell detection and biocompatibility experiments. 
From references (69) and (70). 
 
A biocompatibility assessment of these BiNPs, which were used to target 
and detect specific cell types by X-ray fluorescence spectroscopy, reported a low 
level of cytotoxicity in one study,(69) but the same group also reported some 
cytotoxicity of similar BiNPs that depended on the BiNP surface coating.(70) The 
particles used in the these studies were all synthesized in DMF, and were then 
further reacted in toluene with polyethylene glycol (PEG) or other surfactants to 
give water soluble particles with a range of surface charges and functionalities. 
Specifically this study found that capping BiNPs with a silica shell, or with PEG, 
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produced particles with a slightly lower toxicity in vitro, relative to the unmodified 
particles. Given the difficulty of removing surface bound solvents from high 
surface area materials and purification of particles from toxic solvents or 
reagents, aqueous and/or biologically compatible solvents, such as diols, were 
primarily explored for the synthesis of BiNPs in this document. 
 
Polyol Synthesis of BiNPs 
The polyol synthesis is an ill-defined chemical reaction that has been used 
to produce a wide variety of inorganic nanoparticles. In short, a poly-alcohol 
solvent is heated in the presence of a metal cation, that is then reduced to an 
inorganic nanoparticle.(71) Syntheses of BiNPs have been reported by the polyol 
process,(59, 72–77) where a bismuth(III) or (V) precursor is heated to a specified 
temperature to produce bismuth(0) particles. Additional surfactants can effect 
morphology control of the particles, and will be discussed. The preparation of 
BiNPs in a biocompatible poly-alcohol solvent is a potential non-aqueous route to 
produce medically applicable BiNPs for use as XCAs, provided that the surface is 
adequately protected against oxidative decomposition in aqueous solutions.  
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Figure 1.9. Representative electron microscopy images of bismuth 
nanomaterials produced by the polyol synthesis. All particle syntheses were 
carried out in ethylene glycol heated at reflux. Bismuth(III) citrate was reacted 
with urea and PVP (A and B, from reference 78.) Bismuth(III) acetate was 
reacted with PVP (C and D, from reference 59.) Bismuth(III) chloride was reacted 
PVP with two different (unspecified) concentrations of NaOH to produce non-
spherical particles (E and F, from reference 73.)  
 
Polyol syntheses are most commonly carried out in ethylene glycol, and 
three preparations that used ethylene glycol as a solvent and PVP as a 
surfactant will be discussed here. Cheng et al. reported the used of bismuth(III) 
citrate and urea, which were heated in ethylene glycol to reflux in the presence of 
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PVP under atmospheric conditions.(78) Figure 1.9 A and B show SEM images of 
the particles obtained from this synthesis, which are clearly round and relatively 
size polydisperse. The addition of cetyltrimethylammonium bromide or PEG to 
the reaction produced less well-formed particles that have a higher size 
polydispersity (not shown). Wang and Xia reported the decomposition of 
bismuth(III) acetate in ethylene glycol (heated under reflux) in the presence of 
PVP.(59) Particles produced by this method are shown in Figure 1.9 C and D, 
and are a second part of the same study discussed in section 1.6.1 of this 
document. The authors showed a correlation between the size of the particles 
produced relative to the concentration of bismuth(III) acetate used during the 
synthesis. As this particular study was focused on the formation of low melting 
point elements, specifically the formation of bismuth(0) from the bismuth(III) 
acetate precursor, they additionally noted the effect that stirring rate has on the 
final particle size. 
A polyol process using a BiCl3 starting material and PVP in ethylene glycol 
with and without the addition of NaOH, has been published by two different 
groups, who reported the production of primarily bismuth(0) nanowires. In both 
studies spherical nanoparticles were occasionally noted, and the role of NaOH 
appears to be important for shape control.(73, 79) Specifically, addition of 
hydroxide appears to produce a higher yield of wires in the final nanomaterial 
product. Shown are representative examples of nanoscale bismuth(0) triangles 
(Figure 1.9 E) synthesized with lower additive amounts of NaOH, relative to the 
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amounts used to obtain nanowires (Figure 1.9. F) in the reaction mixture.(73) The 
authors argued that the role of NaOH is to enable the formation a BiO2- 
intermediate bismuth(III) species that dictates the rate of nanomaterial formation 
and thus the shape of the final nanomaterial obtained.  
 
Figure 1.10 TEM images of products of polyol synthesis using a NaBiO3 
precursor. The bismuth(V) precursor is heated in a sealed vessel with ethylene 
glycol and PVP (A) or with acetone at a ethylene glycol to acetone ratio of 1:2 (B) 
or 1:4 (C, from reference 74.) Shape control of BiNPs was achieved in a similar 
synthesis by altering the molar ratio of PVP to bismuth from 0:1 (D), 0.8:1 (E), 
1.6:1 (F) to 5:1 (G, from reference 77.) 
 
The use of a NaBiO3 precursor that is thermally decomposed and reduced 
to bismuth(0) in the presence of a surfactant has been explored in two 
publications, which are unique because they are the only two preparations that 
use a bismuth(V) precursor. In the earlier work by Wang and co-workers, NaBiO3 
was suspended in ethylene glycol in a sealed autoclave vessel with PVP or 
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acetone, that was then degassed and heated to 180 to 200 °C for 24 hours.(74) 
Bismuth(0) nanowires were obtained in the presence of PVP, and bismuth(0) 
spheres were the predominant morphology observed when acetone was present 
in place of PVP. Figure 1.10 A shows a representative TEM image of nanowires 
obtained by this method when PVP was used as a surfactant. Figure 1.10 B and 
C show spherical particles obtained by this method when acetone was present in 
solution at an ethylene glycol to acetone ratio of 1:2 and 1:4, respectively.   
In the latter work by Wang and co-workers, the ratio of bismuth(V) to PVP 
was explored as a way to morphology control the resultant bismuth(0) 
materials.(77) Using a similar synthetic protocol to their previous work, by 
controlling the bismuth to PVP ratio, the authors were able to synthesize spheres 
(Figure 1.10 D), triangles (Figure 1.10 E) and cubes (Figure 1.10 F). Interestingly, 
wires were reported to form in this study only when an iron(III) species was 
added to the synthesis, suggesting that a trace contamination of a transition 
metal in the previous work when wires were regularly produced. The authors 
postulated that the role of iron(III) is to decrease the rate of bismuth(0) formation, 
thus limiting the nucleation rate and increasing the growth rate, which should give 
preferential rise to bismuth(0) nanowires.  
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Figure 1.11. Electron microscopy images of bismuth(0) particles produced by the 
polyol method, from reference (72). Particles were synthesized by boiling 
bismuth(III) hydroxide in 1,3 propane diol (A), diethylene glycol (B), glycerol (C), 
or tetraethylene glycol (D). Particles were also synthesized in propylene glycol by 
reduction of bismuth(III) acetate (E), bismuth(III) nitrate (F), or bismuth(III) 
subcarbonate (G). Additionally particles were synthesized in mixture of propylene 
glycol and triethanol amine that was used to reduce bismuth(III)hydroxide (H and 
I, all from reference 72.)  
 
   A systematic study of the polyol synthesis for the formation of bismuth(0) 
particles by Goia et al. used a variety of diol solvents and reported a wide range 
of particle sizes produced.(72) The authors surveyed polyalcohol solvents, such 
as propylene glycol, 1,3-propanediol, diethylene glycol, glycerol and tetraethylene 
glycol to commonly used ethylene glycol. They also surveyed bismuth(III) 
sources including bismuth(III) nitrate, bismuth(III) acetate, bismuth(III) oxide and 
bismuth(III) carbonate as bismuth precursor materials. The authors suggested 
that the counter-ion and acidity of the bismuth(III) salt may affect particle 
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formation kinetics, but that the solvent boiling point was the most important factor 
for particle morphology control. Interestingly the authors concluded that a 
minimum synthesis temperature of 220 °C is necessary for reduction of 
bismuth(III) acetate to bismuth(0), which was substantially higher than the 
synthetic temperature reported by Wang and Xia in their polyol synthesis.(59) 
However, concentration, Goia et al. used a 200 mM bismuth concentration, Wang 
and Xia used 10 to 70 mM concentration, or the addition of PVP to the reaction 
solution, may be responsible for this disparity.  
The particle morphologies observed in this study were generally spherical, 
albeit the particle sizes obtained under different synthetic conditions were highly 
variable. Figure 1.11 shows some of the particle populations obtained in this 
particular study and were chosen to illustrate size ranges and morphology 
distributions. When bismuth(III) hydroxide was heated to reflux in 1,3-propanediol 
(Figure 1.11 A), diethylene glycol (Figure 1.11 B), glycerol (Figure 1.11 C) or 
tetraethylene glycol (Figure 1.11 D) particles appear generally spherical and very 
size polydisperse. Tetraethylene glycol appears to produce the smaller particle 
population, and glycerol contains a particle population with some of the largest 
particles observed. Propylene glycol was used to produce bismuth(0) particles 
from bismuth(III) acetate (Figure 1.11 E) bismuth(III) nitrate (Figure 1.11 F) and 
bismuth(III) subcarbonate (Figure 1.11 G), and the morphologies observed were 
variable depending on the bismuth (III) counter ion used. The most well 
morphology controlled particles were produced from bismuth(III) hydroxide in a 
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mixture of diethylene glycol and triethanolamine (Figure 1.11 H and I). This 
illustrates the versatility of the polyol reaction for the production of variable 
bismuth(0) materials and is highly promising for the synthesis of biologically 
compatible BiNPs. However aqueous stability of these particles, in addition to 
increasing the homogeneity of particle sizes, would need to be addressed for 
further development of BiNPs for biological application. 
 !
Aqueous Syntheses of BiNPs 
Reported aqueous preparations of BiNPs are rare and the morphologies of 
BiNPs produced in aqueous solutions are in general substantially less uniform 
than particles synthesized in organic solvents (see Section 3.2 for further 
discussion.) An early aqueous phase synthesis of BiNPs was accomplished 
using a reverse micelle method. In this preparation, dioctyl sulfosuccinate sodium 
salt in isooctane was used to form reverse micelles around aqueous BiOClO4, 
which were then reacted with reverse micelles containing NaBH4 to produce 
elemental BiNPs.(80) The resultant particles were morphologically 
heterogeneous and generally smaller than 10 nm. However, the use of micelles 
is a logical approach for nanomaterial synthesis, as the micelles provide a 
confined reaction volume for particles synthesis and should prevent ripening or 
fusing of the produced particles. Additionally the micelles should prevent other 
solvent or environmental reactions with the growing nanoparticles. 
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Figure 1.12 TEM images of BiNPs synthesized in aqueous solvents. Particles 
synthesized from BiClO4 and NaBH4 in reverse micelles (A, from reference 80.) 
BiNPs produced by an emulsion process from bismuth(III) citrate and NaBH4 (B, 
from reference 81 and 82.) BiOClO4 was reduced in water by a γ ray source in a 
70 % (C) or 10 % (D) polyacrylamide solution, or in a 10 % polyacrylamide 
solution with the addition of cadmium(II) ions (E, from reference 83.) BiNPs 
produced from aqueous BiCl3 reduced by hydrazine hydrate in the absence (F) 
and presence (G) of sodium oleate, from reference (84). BiNPS produced from 
bismuth(III) nitrate suspended by tartaric acid in a basic solution, and reduced by 
sodium-hypophosphite over 5 (H) and 10 (I) hours, from reference (85). 
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Fang et al. synthesized bismuth(0) particles in aqueous solution using a 
bismuth(III) citrate precursor reduced by NaBH4 in an emulsion process.(81, 82) 
Poly(oxyethylene)9 nonyl phenol ether and poly(oxythylene)5 nonyl phenol ether 
were used as amphiphilic polymers for micellular formation in petroleum ether, 
with an aqueous solution of ammonium citrate. The particles were subsequently 
washed and suspended in PVP and ethanol to prevent surface oxidation during 
analysis. The TEM images of the particles show polycrystalline aggregates with 
rough surfaces and inhomogeneous morphologies, as well as a high 
polydispersity in nanocrystal size (Figure 1.12 B). Another preparation by the 
same group, using again the microemulsion process, employed a Bi(NO3)3 
starting source and NaBH4 as a reducing agent, albeit with methyl methacrylate 
or hydroxyethyl grafted methyl methacrylate as the amphiphile to form the micro 
emulsion. This preparation produced similarly aggregated and amorphous 
bismuth(0) materials (image not shown.)(86) 
The most morphologically well controlled aqueous preparation of BiNPs 
published to date was accomplished by pulse radiolysis reduction of BiOClO4 in 
water with 2-propanol surfactant using a γ radiation source and either 
polyethyleneimine or polyacrylamide as a capping agent.(83) Briefly, a 60Co 
source provided a 5.2 x 104 rad/h dose to a 100 mL aqueous solution of the 
bismuth(III) source. Using a radiation pulse, the authors argued that the γ 
radiation produced a hydrated electron, an H atom and a hydroxyl radical, and 
that the function of 2-propanol was to scavenge the hydroxyl radical thus 
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producing a reducing environment via an organic radical. The authors showed 
that a change in the final particle size and morphology was possible by adjusting 
the amount of the polymer surfactant. Particles produced in 70% polyacrylamide 
solutions were smaller (Figure 1.12 C) relative to particles produced in 10% 
polymer surfactant (Figure 1.12 D). The addition of Cd(ClO4)2 to the reaction 
solution was used to probe the mechanism of the radiation induced reduction. 
The γ radiation does not reduce cadmium(II) when a bismuth(III) source is not 
present, but colloidal cadmium(0) is produced when colloidal bismuth(0) is 
present as a catalyst. The authors suggest that in this case, the γ radiation is 
unable to reduce the cadmium(II) to cadmium(0) without a bismuth intermediate 
either stabilizing a cadmium(I) intermediate or by direct transfer of charge from 
bismuth(0) to cadmium(II). The bismuth(0) particles produced in 10% polymer 
surfactant solution in the presence of cadmium(II) (Figure 1.12 E) are 
qualitatively similar to particles produced in the absence of cadmium(II) (Figure 
1.12 D), and interestingly if the polymer concentration is decreased, cadmium(0) 
can be deposited on the bismuth(0) particle surface. While the use of a radiation 
source is impractical for the large-scale synthesis of BiNPs in an unequipped 
laboratory, the reducing source is novel and the used of methyl methacrylate as a 
surface passivating polymer is interesting because of the aqueous stability it 
imparts on the BiNPs surface. 
Another aqueous BiNP synthesis was accomplished at 80 °C, and used a 
BiCl3 as a starting reagent, sodium oleate as a surfactant and hydrazine hydrate 
! 49!
as a reducing agent. The authors argued that the reducing agent also helped to 
buffer the pH during synthesis to promote oxidative stability of the BiNPs in 
water.(84) Oleate, as a reactant in an aqueous synthesis, should phase isolate 
the growing BiNPs, which may explain the hydrolytic stability, but it also promotes 
aggregation and agglomeration of particles in water. However, in the absence of 
the oleate surfactant, bismuth(0) material is obtained, but is highly surface 
irregular and inhomogenous (Figure 1.12 F) relative to the bismuth(0) particles 
obtained in the presence of oleate (Figure 1.12 G). Interestingly, this synthesis 
took place at 80 °C, and the authors noted that above 90 °C the reaction took 
place so quickly that bulk bismuth(0) was formed, as evidenced by the 
observation of a highly aggregated and metallic material. Alternately, below 
60 °C, only the formation of a grey precipitate is observed, which is most likely a 
bismuth oxide species. They noted that the morphology of the particles is 
independent of oleate concentration, which is unexpected given the dramatic 
morphology change observed when no oleate was present.  
An aqueous BiNP preparation that used a novel method to suspend 
bismuth(III) cations, used tartaric acid in a basic solution as a ligand to promote 
solubility for the cation.(85) In short, Bi(NO3)3 was reacted with tartaric acid in an 
acidic solution, and sodium hydroxide was added to form a clear, suspended 
bismuth(III) aqueous precursor. The solution was brought to 90 °C, and sodium 
oleate, followed by sodium-hypophosphite, was added and the reaction was 
allowed to stir for 5-10 hours. The authors noted that in the absence of tartate, 
! 50!
under basic conditions, a white bismuth(III) oxide was formed that was difficult to 
further reduce to bismuth(0). The authors also noted that smaller particles were 
obtained when the reaction proceeded for 5 hours (Figure 1.12 H) and that 
relatively large, more rod shaped particles were obtained during the 10 hour 
reaction time (Figure 1.12 I). Varying the tartaric acid concentration had little 
effect on the final particle morphology, but decreasing the concentration of NaOH 
induced the formation of strings of disorganized particles. Increasing the NaOH 
concentration led to an increase in particle polydispersity, and larger particles or 
aggregates were observed. The authors speculated that the concentration of 
NaOH affected the bismuth(III) tartate complex and thus the bismuth(III) 
reduction rate.  
 
1.7 Scope of this Work 
 The scope of this work is to further develop synthetic strategies for the 
formation of bismuth(0) nano and micon scale materials to be used in medical 
applications. BiNPs that are highly X-ray opaque and imputed to contain no toxic 
organic molecules is the primary synthetic aim of Chapters 2 and 3. As BiNP 
synthetic preparations commonly contain toxic organic solvents, are not 
oxidatively stable in aqueous solutions or are poorly morphology controlled, novel 
synthetic routes were undertaken. Chapter 2 describes an aqueous BiNP 
synthesis that uses a previously undescribed BiNP surfactant, dextran, in a pH 
controlled solution. Chapter 3 describes a BiNP synthetic strategy that takes 
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advantage of the solubility of bismuth(III) cations in 1,2-propane diol and uses a 
glucose surfactant to stabilize particles in aqueous solutions. Particles are shown 
to be highly X-ray opaque as characterized by a quantitative CT study, and 
preliminary cytotoxicology results suggest that particles will have cell type 
specific responses.  
 Chapter 4 of this dissertation describes the use of an uncharacterized 
bismuth(III) iodide precursor suspended in hexadecylamine to produce BiNPs by 
an orgaoamine reaction. Particles are putatively amine terminated, and may find 
application in BiNP ligand exchange studies.  
 Chapter 5 of this dissertation describes an inexpensive synthesis of a 
bismuth(0) microparticles for use in highly X-ray opaque composite materials. 
These materials are expected to find application in medical devices for the 
tagging, locating and tracking of X-ray transparent medical equipment.  !!
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Chapter 2 - pH-dependent Synthesis and Stability of Aqueous, Elemental 
Bismuth Glyconanoparticle Colloids: Potentially Biocompatible X-ray 
Contrast Agents 
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2.1 Abstract 
  Taking advantage of a pH-dependent solubility equilibrium, we have 
developed an aqueous synthesis of chemically and colloidally stable bismuth(0) 
glyconanoparticles. The synthetic method results in potentially biocompatible 
elemental Bi nanoparticles (BiNPs) and involves the reduction of aqueous Bi(III) 
cations by sodium borohydride in a pH-controlled solution. Medical grade dextran 
(75,000 MW) was found to protect the nanocrystals from oxidation, in addition to 
promoting colloidal stability and separation of individual nanocrystallites. The rate 
of particle formation was dependent on synthesis pH, and decreasing the 
reaction rate by increasing the pH produced a greater number of individual and 
isolated Bi(0) nanocrystals. Stable, aqueous colloids of the dextran-coated BiNPs 
decomposed under prolonged light exposure, and the NPs dissolved both in 
acidic solutions (pH <7) and highly alkaline solutions (pH >12), but were stable in 
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phosphate buffered saline solution (pH = 7.4) and in other aqueous solutions 
between pH 8 and 10. Bismuth based nanomaterials have previously been 
demonstrated to be long circulating X-ray contrast agents, and we anticipate that 
these bismuth(0) glyconanoparticles will find use in similar applications. 
  
2.2. Introduction 
 Bismuth nanoparticles (BiNPs) have garnered attention recently due to 
their predicted quantum size effects,(1,2) favorable thermoelectric 
properties,(3,4,5) and use as seeds for VLS growth of metal nanowires.(6,7) 
Additionally, the potential of Bi-based nanomaterials has very recently been 
explored as high contrast, long circulating, low-toxicity X-ray contrast agents 
(XCAs).(8,9,10) Nanometer-sized inorganic particles are attractive as XCAs since 
they contain a large number (hundreds or more) of X-ray attenuating atoms in a 
relatively small volume, which should allow for intravenous administration at low 
concentrations, particularly if the particles are site-directed by the addition of 
biological recognition moieties to the surface.(11) The inherent high surface area 
to volume ratio characteristic of nanoparticles can be further advantageous in 
allowing for the addition of high copy numbers of recognition groups to the NP 
surface, thus taking advantage of recognized multi-valency effects in certain 
nanoparticle-biological structure honing interactions.(12) 
Bismuth is an attractive element for nanomaterial XCAs due to its high 
atomic number (Z = 83) and well-known biological tolerance.(13)  The first of 
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these properties will make bismuth-based contrast agents more X-ray opaque on 
a per atom basis than current, clinically used, iodine-based (Z = 53) contrast 
agents; the second should allow for safe use during imaging as well as biological 
clearance after imaging. As an alternative to bismuth-based nanoparticles, heavy 
element gold nanoparticles (AuNPs, Z = 79) have begun to be explored as nano 
XCAs,(14,15,16) primarily due to the ease of synthesis and morphological control 
that has been demonstrated for AuNPs over the last several decades. However, 
gold is currently about two thousand times more expensive per mole(17) and 
approximately half as terrestrially abundant as bismuth,(18) making AuNPs 
substantially less attractive than BiNPs for large-scale, systematic medical 
use.(19) Most importantly, while the oxidative inertness of AuNPs confers a 
synthetic advantage in the laboratory, AuNPs larger than 5 nm pose a toxicity risk 
since they would not be renally cleared,(11) thus making bio-accumulation 
likely.(20) Conversely, elemental BiNPs readily undergo oxidation and hydrolysis 
in water, rendering them difficult to synthesize and stabilize in an aqueous 
environment while simultaneously making them more likely to decompose to 
small, renally clearable, molecular or ionic Bi(III) species in vivo. Medically, Bi(III)-
chelate solutions have been used for centuries in relatively high doses (multiple 
gram doses per day)(21) as safe anti-microbial and anti-emetic treatments with 
minimal known toxicity, despite the fact that these preparations have been 
predominantly chemically ill-defined.(13) Bi(III) complexes present in blood are 
thought to be cleared by urinary excretion via metallothionine, a cysteine rich 
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protein abundant in the kidneys that has been shown to have preferential affinity 
for bismuth over other elements, regardless of pH.(22) 
While the hydrolytic instability of BiNPs may prove advantageous for a 
medical application by providing a mechanism (i.e., biocorrosion) for clearance, 
aqueous synthesis of BiNPs is a substantial challenge as is the stabilization of 
aqueous BiNPs colloids for a time period suitable as an imaging window (up to 
24 hours). The majority of BiNP preparations reported to date are carried out 
anaerobically using organic solvents and morphology controlling surfactants of 
poor or unknown biocompatibility. These syntheses primarily yield hydrophobic 
BiNPs or present challenges for purification from excess, potentially toxic 
reagents prior to a biological application. The elegant synthetic preparations of 
BiNPs by Buhro and others from Bi(N(SiMe3)2)3 produce a variety of well-
controlled shapes and sizes.(23,24,25)  However the use of hydrophobic solvents 
and a specialty block co-polymer for stability makes the products of this 
preparation method non-ideal for medical application. Variations of polyol 
preparations have been reported for the synthesis of Bi nano-structures in 
ethylene glycol, including spheres,(26,27) cubes,(28) and wires.(29) In these 
preparations, PVP is used as a surfactant, stabilizer and morphology-directing 
agent. Although the use of PVP may confer some degree of aqueous stability to 
the particles after work-up, we were unable to find literature evidence that PVP 
prevents surface oxidation and eventual hydrolysis of elemental BiNPs, which is 
commensurate with our laboratory experience with this capping agent. A unique, 
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aqueous preparation of BiNPs uses oleate as a surfactant to form a stabilizing 
barrier against BiNP hydrolysis;(30) however, this hydrophobic barrier also 
prevents colloidal dispersion of the nanocrystals in water. To date, an aqueous 
synthesis method employing biocompatible reagents that yields small (<200 nm 
hydrodynamic diameter), colloidally stable, hydrophilic BiNPs has not been 
reported. An aqueous synthetic preparation (which reduces purification steps and 
minimizes toxicity risks), hydrophilicity, and intermediate hydrolytic stability are all 
requisites for a suitable nanomaterial XCA. 
Herein, we describe a solution method for the aqueous synthesis and 
aqueous stabilization of elemental BiNPs, which are produced by a simple, 
benchtop Bi(III) salt reduction using biocompatible reagents. We also examined 
the quality (size, morphology, extent of aggregation, and period of 
colloidal/chemical stability) of the BiNP products to determine synthesis and 
storage conditions suitable for future utilization of these high atomic number NPs 
in medical imaging. We used Bi(NO3)3•5H2O treated with varying amounts of 
KOH and a standard amount of glycine to control pH, and thus the concentration 
of Bi(III) monomer available for reduction. Short chain medical grade dextran 
(75,000 MW) was used as a biocompatible surfactant in the preparation, and 
sodium borohydride was used as the reducing agent. Dextran is a glucose 
polymer used medically as a plasma volume enhancer and is also commonly 
used to solubilize iron as an intravenous treatment for anemia. In this 
preparation, dextran serves to surface stabilize the BiNPs while promoting 
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colloidal stability in aqueous media and providing reasonably long-term protection 
against hydrolysis, both of which (colloidal and chemical stability) are observed to 
be dependent on pH. While the effect of OH-/Bi(III) ratio on the morphology of Bi 
nanostructures has been reported in non-aqueous media (i.e., ethylene 
glycol)(29) and the effect of OH-/Bi(III) ratio on the kinetics of aqueous bismuth 
hydroxide (Bi(OH)3) particle formation has been examined,(31) to our knowledge, 
this work constitutes the first report on the effect of pH in controlling the aqueous 
synthesis and stability of elemental BiNP. 
 
2.3 Experimental 
Reagents  
Bismuth nitrate pentahydrate (Acros, 98%), glycine (Acros, 99+%, analysis 
grade), KOH (reagent grade), dextran (Carbomer, Inc., 75,000 MW, clinical 
grade), sodium borohydride (MP Biomedicals, 98-99%), and phosphoric acid 
(Sigma-Aldrich, >85%) were purchased and used as received without further 
purification. All solutions were prepared using fresh, electrophoretically pure 
(18 MΩ⋅cm resistivity) H2O.  
 
Synthesis 
All reactions were performed with magnetic stirring at >800 rpm. During 
the reactions, temperature was held constant at 40˚C by immersion of the 
reaction vessel (a 100 mL beaker) in a temperature controlled water bath. In a 
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typical synthesis, 250 mg (0.52 mmol) Bi(NO3)3•5H2O was suspended by 
sonication in 25.0 mL H2O. A 2.00 M glycine solution (10.0 mL, 20 mmol) was 
added to the Bi(III) solution, along with an appropriate amount of 2.0 M KOH to 
achieve a specified pH (e.g., 12.0 mL, 12 mmol, for a measured pH of 9.0). Then, 
7.5 mL of a 100 mg/mL dextran stock solution (750 mg) was added immediately 
prior to the addition of 12.5 mL of a freshly prepared 10 mg/mL (3.3 mmol) 
NaBH4 solution. Upon addition of reducing agent, the solution was observed to 
change from a cloudy, colorless suspension to a black solution in a time frame 
that was dependent on the initial pH of the reaction. After approximately 5 
minutes, when the reactions appeared to have stabilized by visual inspection 
(based on color change) and cessation of gas evolution (H2 from BH4-), all 
solutions were brought to the same pH (7.4) by the drop wise addition of 1.0 M 
H3PO4. Samples were briefly sonicated to promote dispersion and allowed to stir 
for one hour at room temperature prior to purification. 
 
Dialysis and Purification 
The reaction products containing the nanoparticles were dialyzed against 
water using Spectrum* Spectra/Por (50,000 MWCO) dialysis tubing to separate 
the nanoparticles from salts, excess starting reagents, and small molecule 
byproducts. The purified nanoparticle solutions were then centrifuged at 3.0 RCF 
for 10 min to remove large aggregates. Nanoparticles in the supernatant were 
concentrated by rotary evaporation under vacuum (40°C water bath) and stored 
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at room temperature away from light. For long-term storage, samples were stored 
in water either at -20°C or at 4°C with a trace amount of sodium azide to prevent 
biological contamination.  
 
Spectroscopic Analysis of Particle Nucleation, Growth, and Stability as a 
Function of pH 
In order to monitor the reaction progress as a function of pH 
spectroscopically, the reaction was scaled down to keep absorbance/scattering 
values under 2 for the duration of the reactions. A dilute bismuth nitrate stock 
solution of 2.06 mM dissolved Bi(NO3)3•5H2O was prepared and sonicated to 
optical clarity. Glycine, dextran, and KOH stock solutions were also prepared and 
were of the same concentrations as used in the larger-scale preparations. Each 
reaction solution contained a standard final amount of Bi(III) (5.15 µmol), glycine 
(100 µmol), and dextran (75 mg). KOH was added to achieve desired pH values 
in the range 8-10.  Preparations for the reactions took place in the following 
order: 1) appropriate volumes of the Bi(III), glycine, and KOH solutions were 
added to and mixed in 8.0 mL H2O, 2) the pH was measured, 3) dextran solution 
was added, and 4) H2O was added as needed to bring the final volume of each 
solution to 9.9 mL.  Each sample was then divided into three equal volume 
aliquots, which were monitored simultaneously by UV-visible spectroscopy on a 
Varian Cary 100 Bio equipped with stirring capabilities.  Light attenuation (due to 
absorption and scattering by the BiNPs) was measured at 650 nm every 5 
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seconds after the addition of sodium borohydride solution (37.5 µL, 10.57 µmol) 
to each cuvette at t = 0 s. Data were collected simultaneously from replicates at 
each pH and recorded in parallel. Attenuation values at each time point from the 
three replicates for each pH were averaged and plotted versus elapsed time. For 
consistency, all samples were prepared, mixed, and measurements initiated 
within 90 seconds. 
Though all reaction conditions were not exactly identical to those used in 
the large-scale preparations due to measurement requirements, these small-
scale spectroscopic experiments allow real-time observation of reaction stages 
and trends in reaction progress (i.e., rates) as a function of pH; qualitatively, the 
same trends in nucleation periods and growth rates are observed in the large-
scale preparations, although the colloids produced in the large-scale preparations 
are, in general, colloidally stable for longer time periods (days versus hours). 
 
Product Characterization 
UV−visible spectra for the products of the large-scale preparations were 
collected on a Shimadzu UV-2450 UV−visible spectrophotometer in standard 1-
cm disposable polystyrene cuvettes.  
Dynamic Light Scattering (DLS) measurements were taken on a Horiba 
LB-550 dynamic light scattering instrument. Samples were purified as described 
above, diluted in water, and passed through a 0.45 µm PTFE syringe filter prior to 
measurement. Measurements (300 scans) at 5 different concentrations of each 
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sample were performed in order to determine a size distribution independent of 
concentration effects (e.g., multiple scattering).  
Transmission Electron Microscopy (TEM) was performed on an FEI 
Tecnai F-20 TEM operating at 200 kV. Purified samples were drop-cast on Ted 
Pella holey carbon copper supported grids and dried for 2 hours at 150°C prior to 
imaging. Energy Dispersive X-ray (EDX) spectroscopy was performed on a 
representative sample of 20 individual particles during TEM imaging.  
FT-IR spectroscopy was performed on a Thermo Scientific Nicolet iS10 
spectrophotometer equipped with a single-bounce diamond attenuated total 
reflectance (ATR) attachment. Aqueous solutions of purified BiNPs, dextran, and 
glycine were drop-cast onto the ATR crystal and the solvent was evaporated as 
necessary using a heat gun to deposit a sample film for analysis. 
For XRD analysis, concentrated BiNP samples were evaporated to 
dryness in a ceramic evaporation dish in air, milled into a fine powder, and 
pressed onto a glass slide. Data were collected in focused beam (Bragg-
Brentano) geometry on a Rigaku Ultima IV X-ray diffraction system using 
graphite monochromatized Cu Kα radiation. Scans were performed over the 
angular range 5-85° 2θ at a scan rate of 0.25°/min at room temperature. 
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Results and Discussion 
 2.4 Synthesis  
For future X-ray contrast applications, we have developed an aerobic, 
aqueous solution method for the preparation of chemically and colloidally stable, 
water-soluble, potentially biologically compatible BiNPs, which should have the 
following advantages over existing BiNP preparations: 1) it negates the need for 
phase transfer steps post-synthesis, 2) it simplifies preparation and purification 
steps in employing highly biocompatible starting materials, and 3) it reduces 
overall environmental impact. The starting material, bismuth nitrate pentahydrate, 
was chosen as an inexpensive, readily available, and easily dissolved (at low pH, 
or in dilute aqueous solutions) Bi(III) source. To reduce Bi(III) to elemental form, 
sodium borohydride was chosen, as this reducing agent should decompose in 
aqueous solution to gaseous products (H2 and borates) and a soluble sodium salt 
that can easily be removed by dialysis. A surface stabilizing ligand or polymer 
was necessary to achieve chemically and colloidally stable, elemental BiNP, and 
in our preparation, the glucose polymer dextran was found to impart both 
oxidative and colloidal stability to the BiNPs if the particles were formed slowly 
(i.e., over a duration of 1-10 minutes).  The solubility of the Bi(III) source as a 
function of pH was found to dramatically affect the extent of aggregation and 
colloidal stability of the BiNP products (Scheme 2.1), which we discuss below.  
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Scheme 2.1. pH-Dependent Synthesis of Colloidally Stable Glyco-BiNPs 
 
Visibly we observed a reaction progression in which both nucleation period 
and growth rate are dependent on synthesis pH. Treatment of a colorless 
solution or white suspension of Bi(NO3)3•5H2O in the presence of glycine and 
dextran with reducing agent resulted in the evolution of a brown, and ultimately a 
black, solution color (Figure 2.1 a-e). The elapsed time to obtain an initial brown 
color, indicative of the beginning of particle nucleation, and the elapsed time to 
obtain the stable black color, indicative of the formation of larger bismuth(0) 
nanocrystallites, were noticeably longer with increased reaction pH. In the 
absence of the carbohydrate surfactant, black BiNP were visibly formed (the 
rhombohedral bismuth(0) phase was confirmed by PXRD) upon addition of the 
reducing agent to the aqueous Bi(III) precursor. However, these bismuth(0) 
particles quickly aggregated, precipitated out of solution, and eventually 
underwent oxidation and hydrolysis, resulting in the formation of an unidentified, 
white amorphous solid. Using glycine as a biocompatible buffering agent with 
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amine pKa of 9.8 and medical grade 75,000 MW dextran as a polymeric surface 
stabilizer, we spectroscopically determined the optimal pH range for the 
synthesis of colloidally stable, aqueous BiNPs that do not aggregate or 
decompose to oxidized products (e.g., Bi(III) solids, such as Bi(OH)3 or Bi2O3, or 
Bi(III) solution species, such as BiO2- or BiO33-) for periods as long as 12 months 
when appropriately (vide infra) stored in aqueous solution.  
 
Figure 2.1. Nucleation period and growth rate of BiNPs are dependent on the 
reaction pH. (a-f) Treating a colorless solution or white suspension of bismuth 
nitrate in the presence of glycine and dextran (panel a) with reducing agent leads 
to the development (panels b-e) of a black colloid of bismuth nanoparticles (e) in 
a time frame that is pH- dependent. Particle synthesis in the absence of 
surfactant or at pH <8 resulted in unstable aggregates (f). (g) Reaction 
progression monitored by light attenuation at 650 nm for solutions at measured 
pH values of 9.12 (blue), 9.62 (red), or 9.73 (green). 
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The effect of pH on the reaction progression and rate is shown in Figure 
2.1 g. To monitor the BiNPs formation as a function of pH in situ, UV-visible 
spectroscopy was performed on small-scale preparations using initial reagent 
concentrations that yielded products with suitable attenuation values (<2 arbitrary 
units). Light attenuation, the combination of absorption and scattering, at 650 nm 
was measured and is indicative of the reaction progression, i.e., the formation of 
black, visible light absorbing/scattering particles. The attenuation versus time 
plots (Fig. 1g) indicate that the reactions proceed in three phases: an initial 
nucleation phase with no attenuation, a particle growth phase indicated by a 
dramatic increase in attenuation, and finally a steady-state phase indicated by a 
plateau in attenuation. Under certain conditions, e.g., low (<8) pH syntheses, a 
fourth aggregation phase is observed (Figure 2.1 f), which is evidenced by loss of 
attenuation as the particles precipitate (data not shown). The time period of the 
nucleation phase is strongly pH dependent and is longer at higher pH values. 
The rate of particle growth, as indicated by the change in attenuation with time 
(i.e., the slope of the growth regime in Fig. 1g), is also pH dependent and is 
slower at higher pH values. Regardless of synthesis pH, all samples reach an 
absorbance plateau corresponding to a steady state phase in which the 
composition of the solution does not appear to change with time. Experimentally, 
we observed that at a low reaction pH (≤ 8.0), large aggregates of elemental 
BiNPs were formed in the presence of dextran; these aggregated particles did 
not oxidize or decompose, as evidenced by the black color of the precipitated 
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solid and confirmation of the rhombohedral bismuth(0) phase by PXRD. 
However, the large aggregates of elemental BiNPs synthesized at pH ≤ 8.0 could 
not be re-dispersed in water, even with durative sonication, to achieve stable 
aqueous colloids. We found that increasing the reaction pH (up to pH=10.5) 
produced a greater number of isolated BiNPs (Scheme 2.1) that did not undergo 
gravitational settling, thus resulting in stable, aqueous Glyco-BiNP colloids. At pH 
values above 11, no reaction was visually or spectroscopically observed, 
presumably due to lack of soluble Bi(III) for reduction (vide infra). For colloidally 
stable samples synthesized in solutions with pH values between 9 and 10, dilute 
phosphoric acid was added drop wise to achieve final solutions at a 
physiologically relevant pH of 7.4 without loss of either colloidal or chemical 
stability.  
 A nanoparticle formation mechanism consistent with the pH effects we 
observe in the aqueous synthesis is shown in Scheme 2.1. For simplicity we 
assume that a suspension of solid bismuth hydroxide is in equilibrium with 
aqueous Bi(III) and hydroxide ions and that the equilibrium is dependent on pH, 
with a decreased Bi(III) concentration achieved by increasing pH according to 
LeChatlier’s principle. When the soluble Bi(III) precursor is depleted by reaction 
with the reducing agent to form bismuth(0) nanoparticles, the solubility 
equilibrium shifts to replenish the solution precursor at the expense of the 
precipitate. Thus, the pH-dependent dissolution of the solid should allow for 
kinetic control over BiNP nucleation and growth by modulating the concentration 
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of soluble Bi(III) monomer available for reduction. Consistent with this, we 
observe that both nucleation and growth are faster the lower the synthesis pH, 
which is correspondent with higher available Bi(III) concentration for reduction in 
more acidic solutions. Also consistent with this, at pH ≤ 8, not enough isolated 
BiNPs are formed to result in a stable aqueous colloid because the saturation 
concentration for nucleation and growth is too rapidly achieved, resulting in the 
formation and precipitation of aggregated nanocrystallites. Notably, the largest 
difference in the reaction products synthesized at different pH values is not the 
individual bismuth nanocrystallite size, but the extent of nanocrystallite 
aggregation, and thus the size and weight of the glyco-BiNP (where a glyco-BiNP 
contains one or more than one Bi nanocrystallite). If Bi nanocrystals are formed 
quickly, as occurs in the lowest pH reactions, this presents opportunity for 
multiple nanocrystalline domains to be encapsulated within a single polymeric 
structure. However, if particles are formed slowly, there are fewer present in 
solution at any given time prior to particle capping (a fast step) by the polymer, 
thus reducing the opportunity for inclusion of multiple Bi nanocrystals in a single 
polymer structure and, consequently, reducing the Glyco-BiNP size and tendency 
for gravitational settling. 
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Figure 2.2. Titration of aqueous Bi(III). Bi(NO3)3⋅5H2O (242 µmols) was dissolved 
by sonication in 100 mL H2O (2.42 mM). Titration with 1.0 M KOH was performed 
in increments of 50 µmol (50 µL) to 700 µmol of added base, and increments of 
25 µmol (25µL) up to 775 µmol, with the presence of a pH probe and rapid 
stirring. Arrow indicates visual onset of precipitation and dashed line indicates 
calculated 3 molar equivalents of hydroxide. 
 
Thus, the pH-dependence of BiNP colloidal stability is influenced by a 
complex pH-dependent solubility equilibrium involving sparingly soluble Bi(III) 
oxide, suboxide, hydroxide, or perhaps, in this case, glycinate precipitates. 
Dependent upon the counter-anion, a wide range of oxidized precipitates have 
been reported for dissolved Bi(III) salts.(32) Though we made no attempts to 
identify either the precipitate or the solution precursor, Bi(III) is known to form a 
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highly acidic (pKa = 1.1) aquo-cation in dilute solution; in concentrated solution or 
upon titration with base, aqueous Bi(III) is expected to form an insoluble basic 
salt that will be in pH-dependent equilibrium with a soluble Bi(III) 
species.(31),(33) Consistent with this, the Pourbaix diagram for bismuth in 
aerated water indicates that the predominant form of bismuth will be an oxidized 
solid over most of the pH range.(34) A titration curve for Bi(NO3)3•5H2O (Figure 
2.2) indicates that the onset of precipitation in dilute solution (2.42 mM) occurs at 
approximately pH = 4 and prior to the addition of 3 molar equivalents of 
hydroxide. Qualitatively, the same results were observed when Bi(NO3)3•5H2O 
was titrated in the presence of glycine; thus we expected and observed a 
significant amount of solid precipitated precursor in our syntheses at all tested pH 
values, and will be discussed in detail in the following section. However, 
regardless of the identity of the solution precursor and sparingly soluble solid, 
controlling pH will control the Bi(III) concentration available for reduction, 
consistent with our spectroscopic observations and proposed aqueous formation 
mechanism. Notably, the successful aqueous synthesis of hydrophobic, oleate-
capped BiNP was performed under basic conditions using hydrazine hydrate.(30) 
 The impact of a variety of other synthetic factors on particle formation 
kinetics and product colloidal stability was measured spectroscopically, including 
the addition of salts (e.g., NaCl, KNO3), buffering agents other than glycine (e.g., 
bicine, tris), and buffer concentration. In all cases, we observed a pH dependent 
nucleation and growth period with the colloidal stability correlated to synthesis pH 
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more than any other factor and with the most stable colloids achieved in solutions 
between pH values of 9 and 10.  
 
2.5 Discussion of Aqueous Bi(III) Chemistry 
The chemistry of aqueous Bi(III) is complicated by multiple precipitate 
types and counterion influences. The fully hydrated Bi(III) cation, i.e., [Bi(OH2)6]3+, 
can lose up to 3 protons to yield the sparingly soluble, neutral species 
Bi(OH)3(OH2)3 (equivalent to Bi(OH)3), which can continue to hydrolyze to the 
thermodynamically stable and insoluble Bi2O3. However, the aqueous solution 
form of Bi(III) is also dictated by the identity of its counterion, for example, 
bismuth oxychloride and other oxo-chloride complexes are formed when bismuth 
chloride is hydrolyzed.(18,35) Bi(III) nitrate solutions at high pH include several 
large rather exotic, hydrolyzed bismuth polyanions, (e.g. Bi4O7, Bi2O5 and 
[Bi6(OH)12]6+)(36,32) or sparingly soluble sub-oxides (e.g. bismuth subnitrate 
BiO(NO3).)(31) The Pourbaix (pH/potential predominance) diagram for bismuth 
reveals that the predominant species of bismuth in aerated water at a neutral to 
basic pH is Bi2O3 solid, and that at lower pH values, the fully hydrated cation 
becomes more stable.(34) Thus, in our syntheses, which yielded colloidally 
stable particles only in solutions between pH 8 and 11, a significant amount of 
suspended Bi(III) solid should be present initially. We observed this 
experimentally in our titration (Figure 2.2) of a dilute (240 µM), optically clear 
solution of the Bi(NO3)3•5H2O starting material with KOH, which we used in our 
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syntheses in addition to glycine to adjust pH. Even in dilute solution, we observed 
the onset of precipitation around a measured pH of 4 and prior to the addition of 
three molar equivalents OH-. Qualitatively, the same results were observed when 
Bi(NO3)3•5H2O was titrated in the presence of glycine. The titration curve is 
familiar as that of a weak acid with an equivalence point reached around 3 molar 
equivalences of KOH. However the exact equivalence point is not easily 
discerned as various oxide precipitates are formed and disrupted during solution 
equilibrium. The identity of the Bi(III) cation and the sparingly soluble solid in 
equilibrium with it will depend on available countercations (e.g., Bi(NO3)3•5H2O is 
known to decompose in H2O to a wide variety of oxide complexes).(32) We 
assume that in our reactions the Bi(III) oxide precipitate is in equilibrium with its 
component ions (Bi3+ and 3OH-) which has be previously studied as a function of 
hydroxide concentration.(33) Regardless of the identity of the solution precursor 
and sparingly soluble solid, controlling pH will control the [Bi3+] available for 
reduction, consistent with our spectroscopic observations and proposed aqueous 
formation mechanism.  
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Figure 2.3. (a, b, d) Transmission Electron Microscopy (TEM) images of BiNPs 
synthesized at pH 9.97: (a,b) the majority of particles appear spherical, although 
triangles, cubes, and hexagons are also visible. (c) Histogram showing 1040 
particles manually measure with a core mean diameter of 19.5 ± 3.7 nm. (d) 
High-resolution TEM image of a single particle with line spacing (3.32 Å) 
characteristic of elemental bismuth.  
 
2.6 Characterization 
Transmission Electron Microscopy (TEM) was used to analyze BiNP 
morphology, size, and crystallinity (Figure 2.3 a,b). Various crystallite 
morphologies were observed, regardless of synthesis pH, including: spheres, 
triangles, hexagons and rods. However, >50% of particles were spherical in all 
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cases. TEM images of colloids synthesized at a pH of 9.97 indicate a free-
standing particle diameter of 19.5 ± 3.7 nm (Figure 2.3 c). Under high resolution 
TEM, a lattice spacing of 0.332 nm was measured (Figure 2.3 d), consistent with 
the d-spacing (0.328 nm) corresponding to the [012] planes of bulk elemental 
bismuth (JCPDS Card No. 00-044-1246). EDX analysis was performed on 20 
isolated particles using the same sample grid and only the elements Bi, O, C and 
Cu (from the grid support) were found. The presence of bismuth was localized to 
the particles, i.e., no bismuth was detected outside of the dark crystallites visible 
on the TEM grid.  
The dried colloids were analyzed by powder X-ray diffraction, and the 
resulting diffraction pattern is largely that of rhombohedral elemental bismuth 
(Figure 2.4a, blue trace, JCDPS Card No. 00-044-1246, tick marks indicate 
calculated reflections), consistent with the high resolution TEM analysis. Other 
reflections apparent in the pattern (17.52, 18.83, 20.25, and 28.80° 2Θ) were 
attributed to crystallized dextran (Figure 2.4 a, purple trace). 
The FT-IR spectrum (Figure 2.4 b) of the dialyzed particles (blue trace) 
matched the spectrum collected for neat dextran (purple trace). Importantly the 
absence of carboxylate peaks at 1593 and 1408 cm-1 and amine deformation 
peaks at 1527 and 1502 cm-1 (37) indicates that glycine served only as a 
buffering reagent during synthesis and did not become part of the BiNP complex. 
This was somewhat surprising given that oleic acid and other carboxylate 
containing species are commonly observed to be surface terminating ligands in 
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other BiNP preparations.(30,38) Particles appear to be coated solely in dextran 
and thus can be accurately termed glyco-BiNP.  
 
Figure 2.4. X-ray diffraction and FT-IR absorbance of BiNPs. (a) Powder X-ray 
Diffraction (PXRD) shows BiNPs (blue trace) to be composed of crystallized dextran 
(purple trace) and elemental bismuth (calculated Bragg reflections for rhombohedral 
Bi indicated by tick marks). (b) FT-IR spectra of purifed, dextran- stabilized BiNPs 
thin flms (blue trace), glycine (red trace), and dextran (purple trace). 
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Dynamic light scattering (DLS) measurements on colloids synthesized at 
pH 9.97 indicated the mean hydrodynamic diameter to be 60 nm after filtration 
through a 0.45 µm syringe filter. The difference (~40 nm) between the crystallite 
size (diameter = 19.5 nm) measured by TEM and hydrodynamic size (60 nm) 
measured by DLS can be attributed to a surfactant and water shell, which 
presumably imparts colloidal stability and solubility to the particles and prevents 
or slows hydrolysis and oxidation. DLS data in comparison with TEM data are 
shown in Figure 2.5. Notably, the syringe filter pre size doesn’t appear to affect 
the crystallite diameter, as measured by TEM, but does decrease the 
hydrodynamic size, as measured by DLS. This could indicate that either the filter 
is size selecting a population with a smaller hydrodynamic size, or that the filter is 
removing some of the organic surfactant on the particles, thus reducing the size 
of the BiNPs.  
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Figure 2.5. Hydrodynamic diameter of BiNP populations change depending on 
size of syringe filter. Glyco-BiNPs were syringe-filtered through 450, 200, or 
100 nm pore diameter PTFE syringe filters and either diluted in water for DLS 
analysis or drop cast and dried on a carbon coated TEM grid. 
 
2.7 Stability and Degradation 
 To examine the colloidal stability of the BiNPs over time, purified, 
concentrated BiNPs were redispersed in aqueous solutions of varying pH values 
using 1.0 M phosphoric acid adjusted with KOH to achieve specified pH values in 
the range 2-12; these samples were protected from light. Additionally, two 
samples were redispersed in water; one was stored in the dark and the other was 
exposed to sunlight. Visual observation (Figure 2.6 a-c) and UV-visible 
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spectroscopy (Figure 2.6 d) were used to monitor the stability of the colloids, 
which was indicated by the maintenance of a dark solution color and the absence 
of precipitates.  
When BiNPs were introduced to the pH=2 solution, the particles 
immediately dissolved, as evidenced by the loss of solution color and absence of 
precipitate. Samples in solutions at pH values of 4, 6, 7, and 12 initially retained 
their color, but fully dissolved to yield colorless solutions within 24 hours; the low 
pH results suggest that the acidic environment of a lysosome would decompose 
these particles in vivo. However, samples redispersed in solutions at pH = 8 and 
10 were colloidally stable for over one month, as was a control sample diluted in 
nanopure water. The latter result suggests that phosphate ions may assist 
degradation over some pH range, but the effect of ion identity and solution ionic 
strength on BiNP stability was not further examined. 
 Photodegradation was examined by preparing two samples of dilute 
colloidal solutions of BiNPs in glass scintillation vials. One sample was exposed 
to ambient light, and one sample was protected from light by a single layer of 
aluminum foil. Both samples were placed side by side in a window, and after 2 
weeks the sample exposed to light had notably decreased in color intensity 
(Figure 2.6 c).   
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Figure 2.6. Stability of BiNPs in phosphate buffered solutions and exposed to 
light. (a-c) For pH stability experiments, purified BiNPs were diluted in 1.0 M 
phosphate solutions and the pH was adjusted with KOH to achieve solutions 
ranging in pH from 2 to 12; light/dark controls were diluted in water and 
visually analyzed at the same time points. All vials were examined for solution 
color and presence or absence of precipitates at time points of (a) 5 min, (b) 
24 h, and (c) 14 days. (d) For spectroscopically monitored light stability 
experiments, purified colloids were diluted in H2O and spectra taken at time 
points of 0, 10, and 14 days. Light-exposed samples were placed in vials in 
direct sunlight and all other samples were stored in vials wrapped in aluminum 
foil; absorbance was monitored at 650 nm. 
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To spectroscopically monitor for photo-degradation, a dilute solution of 
BiNPs was initially divided into two cuvettes and the UV-visible spectrum of each 
was recorded daily over a period of 16 days (Figure 2.6 d). One cuvette was 
wrapped in aluminum foil and both cuvettes were placed in direct sunlight; care 
was taken not to agitate the samples in between measurements in case settling 
of particles or precipitate formation occurred. Initially, both samples showed 
identical broad absorption spectra, covering the entire visible range with 
shoulders in the absorption spectra apparent around 375 nm. The sample 
constantly exposed to light lost absorbance intensity uniformly across the visible 
spectrum, and changed from a dark solution to a light brown solution slowly over 
the course of several days. Conversely, the sample stored in the dark appeared 
to be much more stable, as evidenced by a much slower loss of intensity over 
time. The photo-instability of these particles is unsurprising given their high 
visible light absorption cross-section and may represent an alternative 
decomposition and clearance route for elemental BiNPs employed as XCAs.  
 The BiNP colloids were also tested for temperature stability by freezing 
and boiling BiNP samples redispersed in nanopure water. BiNP samples diluted 
in water and heated to boiling for greater than one hour remained colloidally 
stable, without loss of solution color or formation of precipitates. Additionally, 
water-dispersed BiNPs were slowly frozen (-20°C) and rapidly frozen in liquid 
nitrogen; neither treatment reduced the color intensity or colloidal stability of the 
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particle solutions upon thawing. These experiments indicate that the glyco-BiNP 
colloids are robust over a wide range of temperatures.  
 
2.8 Conclusion 
 The recent popularity of green chemical techniques has put an emphasis 
on using water as a solvent for the synthesis of nanomaterials, and water 
solubility and stability are required for nanomaterial X-ray contrast agents. These 
features are difficult to achieve in oxidatively prone elements such as bismuth. 
Furthermore, the synthesis of elemental nanomaterials by reduction of cations 
often requires a strong reducing agent and controlled kinetics to avoid formation 
of bulk materials and to promote uniform particle growth. Herein, we have 
described a synthesis method that takes advantage of a sparingly soluble solid to 
kinetically slow the formation and growth of Bi nanoparticles in water by 
controlling the pH, and thus the concentration of Bi(III) monomer in solution 
available for reduction. The method allows sufficiently slow growth at modestly 
basic pH values (pH = 8-10) to result in isolated and colloidally stable, rather than 
aggregated and precipitated, Bi nanoparticles. The glucose polymer dextran is 
used to surface stabilize the nanoparticles and promote chemical and colloidal 
stability. The glyco-BiNP can be purified and redispersed in water or in a mildly 
basic phosphate buffer, and these solutions are then stable for months when 
stored away from light.  
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In summary, chemically and colloidally stable, glyco-BiNPs have been 
synthesized using a simple, pH-controlled, aqueous method. These high atomic 
number glyco-BiNP have size, solubility, and stability characteristics suitable for 
use as nanomaterial X-ray contrast agents. Bismuth is known to be both highly X-
ray attenuating and biologically compatibility, which makes elemental bismuth 
nanoparticles good candidates for in vivo nano-scale XCAs. We anticipate future 
experimentation with these particles to include toxicity evaluation and 
determination of X-ray attenuation coefficients at diagnostic X-ray voltages. 
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Chapter 3 - Ultra-High Payload Elemental Bismuth Nanoparticle X-ray 
Contrast Agents: Synthesis, X-ray Opacity, and Biological Compatibility 
 
Adapted from: 
 Manuscript in preparation by: Anna L. Brown, Pratap C. Naha, Harold I. 
 Litt, David P. Cormode, Andrea M. Goforth 
 
3.1 Abstract 
 The development of novel inorganic nanoscale X-ray Contrast Agents 
(XCA) offer many advantages over currently used intravascular molecular 
contrast agents, including longer circulation and retention times, lower 
administration volumes and the potential for site directed imaging. Elemental 
bismuth nanoparticles (BiNPs) are particularly attractive research level XCAs due 
to the low cost of bismuth, the high atomic number and high density of bismuth, 
and the probability that BiNPs will oxidatively decompose to biocompatible 
bismuth(III) ions at controlled rates. Herein we describe the synthesis of ultra-
high payload BiNPs in 1,2-propane diol using a borane reducing agent and 
glucose as a biocompatible surface stabilizer. Particles have large inorganic 
cores (74 nm by TEM) to hydrodynamic size (86 nm by DLS) indicating that the 
majority of the particle volume is constituted of a contrast generating inorganic 
core. Both synthetic solvent (1,2-Propane diol) and surfactant (glucose) appear 
on the BiNP surface, as evidenced by 1H-NMR and FT-IR spectroscopies. These 
BiNPs have a high X-ray opacity, measured by quantitative computed 
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tomography and a minimal cell type specific cytotoxicty. We discuss these 
particles as novel nanomaterial XCAs, surface stabilized by known biologically 
compatible organic molecules, with an ultra-high payload to volume ratio. 
 
3.2 Introduction 
Nanoscale X-ray Contrast Agents (XCAs) are an attractive new class of 
potentially non-nephrotoxic contrast materials, which can evade kidney filtration 
because of large size(1) and offer the prospect of blood pool and site directed X-
ray imaging.(2, 3) The X-ray attenuation coefficient (μ) of a contrast material is 
related to atomic number (Z) and density (ρ) by the expression μ = ρZ4/AE3, 
where A is the atomic mass of X-ray absorbing atoms and E is the incident X-ray 
energy.  Inorganic nanocrystal XCAs are commonly composed of higher (Z) 
atoms than current, clinically applied molecular contrast agents containing iodine 
(Z = 53) and barium (Z = 56), and because the attenuation coefficient is 
dominated by the Z term, elements with higher Z values should therefore offer 
superior X-ray contrast.  Furthermore, the high density of atoms in inorganic 
nanocrystals, which is far greater than the density of high Z atoms in clinical 
small molecule XCAs, allows for a high X-ray attenuation per unit volume of 
contrast material, which is required for CT and site-directed X-ray imaging.(2) 
The elements bismuth and gold are uniquely suited for use as functional 
inorganic nanocrystal XCAs, as they have high atomic numbers, high densities, 
and low reported toxicities. Gold nanoparticles (AuNPs) have previously been 
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explored as XCAs, and site-directed imaging, long circulation times, and evasion 
of kidney filtration have been demonstrated in animal studies.(4–9) However, the 
high price and high utility of bulk gold (currently approximately $8,950/mol(10)) 
coupled with some reports of AuNP toxicity arising from bioaccumulation,(11–13) 
complicate further development and clinical application studies of AuNPs. 
Bismuth nanoparticles (BiNPs) should be significantly less expensive than 
AuNPs, (bulk bismuth is currently approximately $4/mol(14)) and potentially less 
likely to bioaccumulate than AuNPs, and will also have a higher Z (Z = 79 Au, Z = 
83 Bi), which may result in greater X-ray contrast. Notably, bismuth is the highest 
Z negligibly radioactive element(15) and uncommonly for a heavy metal the 
element and its compounds, generally containing bismuth(III) ions, are 
biologically well tolerated in large quantities when ingested.(16) The fate of 
bismuth and other nanomaterials when administered intravenously is unknown, 
but the expecation from limited blood serum data from orally administered bulk 
bismuth(0) and bismuth(III) compounds is promising for BiNP biological 
compatibility, but does not account for other possible toxicity concerns. 
Bismuth(III) compounds are some of the most commonly used over-the-counter 
medications world-wide, and bismuth(III) plasma concentrations up to 50 µg/mL 
are generally considered safe,(17) suggesting that the soluble bismuth(III) 
oxidation product from decomposed BiNPS should pose a minimal toxicity risk. 
Bismuth(III) compounds have been safely used medicinally for centuries, 
despite the poorly characterized formulations of administered compounds and 
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minimal understanding of therapeutic mechanism and fate.(18) More recently, 
reports of bismuth-based nanoparticulate XCAs for blood pool imaging have 
included Bi2S3 nanoparticles stabilized by biocompatible PVP polymer,(19, 20) 
bismuth ions aggregated into polymer nanoclusters,(21) and ~20 nm PVP coated 
elemental BiNPs used in 3D cell detection in a microtissue assay.(22, 23) Of 
these examples, the latter represents the more ideal nanoparticle XCA because 
its X-ray opaque portion is composed entirely of densely packed, high Z atoms. 
While the optimal size of inorganic nanocrystals for use as XCAs is not 
convincingly established, synthetic methods that yield large payload (> 50 nm 
dense cores), morphologically uniform, and biocompatible BiNPs are needed for 
further exploratory studies. However, relative to other inorganic nanocrystals (e.g., 
gold, silver, cadmium selenide, iron oxide, etc.), synthetic methods to produce 
BiNPs are in their infancy.  
To date, elemental BiNPs have been prepared via several synthetic routes 
(see section 1.6 of this thesis) which can be grouped into two main types:  1) 
non-aqueous routes, where a dissolved bismuth(III) precursor is thermally or 
chemically reduced in an organic solvent, such as hexadecylamine/toluene 
cosolvent,(24) cyclohexane,(25) tetrahydrofuran,(26) N,N-dimethylformamide,(22, 
27) 1,3-diisopropylbenzene, (28–31) or ethylene glycol,(32–34) sometimes in the 
presence of an additional surfactant or polymer, and 2) aqueous routes, where a 
bismuth(III) salt solution or suspension is chemically reduced, generally in the 
presence of surface stabilizing surfactants or polymers. While aqueous 
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preparations are perhaps more desirable for product biocompatibility 
considerations, non-aqueous preparations have in general resulted in better size 
and morphology control, which is likely related to the generally poor solubility of 
bismuth(III) precursors in water.(18, 35–37) 
 Perhaps the best size and morphology control over BiNPs has been 
demonstrated in the thermal or chemical, non-aqueous reduction of 
Bi(N(SiMe3)2)3 in apolar solvents, (24, 29, 30) though the resultant products are 
non-aqueous, and potentially surface coated to some degree with the organic 
solvents used in synthesis. Thermal polyol reduction reactions of dissolved 
bismuth(III) in putatively benign polyalcohol solvents, most commonly in ethylene 
glycol, have been accomplished, but generally result in both poor morphology 
and size control of the bismuth nanocrystals. Finally, aqueous BiNP preparations 
are rare and suffer many setbacks in size, size polydispersity and morphology 
control, due to poor and pH-dependent solubility of bismuth(III) ions in water. 
Three successful examples of aqueous preparations are our pH-dependent 
synthesis, which yields small (20 nm) somewhat polydisperse BiNP cores that 
are embedded in a large (60 nm) dextran-polymer shell,(38) the aqueous 
reduction of bismuth(III) salts by either aqueous hydrazine in the presence of 
sodium oleate, (39)  or sodium-hypophosphite in the presence of tartaric acid and 
sodium oleate (40) which ultimately yields 25-40 nm highly hydrophobic particles. 
For both of these preparations particles appear highly aggregated, suggesting 
the oleate surfactant yields surface hydrophobic particles. 
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Since synthetic methods capable of achieving ultra-high payload, size- 
and morphology-controlled, biologically compatible BiNPs ideally suited for use 
as XCAs have not been reported, we set out to achieve a scalable (in quantity) 
and controllable (in size and morphology) synthesis for BiNPs that employs 
biologically benign reagents and results in large (> 50 nm), highly X-ray opaque, 
aqueous BiNP colloids.  Herein, we report the synthesis of large (74 ±14 nm) 
BiNPs by chemical reduction of dissolved bismuth(III) nitrate in 1,2-propanediol 
(PPD), which uses glucose as a biocompatible small molecule surfactant. 
Though the synthesis is non-aqueous, PPD is inexpensive, regarded as 
biocompatible, and is capable of solubilizing bismuth(III) precursors at high 
concentrations.  For BiNPs synthesized at 80°C, we demonstrate a high clinical 
X-ray opacity in body phantom and cellular CT imaging studies.  Furthermore, 
BiNPs produced by this method do not result in decreased cell viability with short 
exposures (1 hour) to either HeLa or macrophage cells, but do result in 
decreased viability for macrophage cells at long (24 hour) exposures.   
 
3.3 Experimental and Methods 
Synthesis of BiNPs 
In a 250 mL beaker, 54 g α-D-glucose, (Acros Organics, >99+%, anhydrous) was 
partially dissolved in 84 mL 1,2-propanediol (PPD, Acros Organics, 99%) by 
immersion of the beaker in a temperature-controlled oil bath with mechanical 
stirring. To this mixture, 4 mL of a 250 mM bismuth nitrate pentahydrate (Acros 
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Organics, 98%) solution in PPD was added, and the temperature was increased 
to a synthetic reaction temperature varying between 60 and 100°C. Borane 
morpholine (Acros Organics, 97%) dissolved in PPD (250 mM) was added (12.2 
mL) to initiate particle formation. The reaction was stirred for 60 seconds after 
addition of reducing agent and then quenched by pouring the beaker contents 
into 200 mL of electrophoretically pure ice water. To obtain larger quantities of 
particles for biological assays, batches of particles were pooled prior to work up 
and purification. For syntheses using surfactants other than glucose, an 
equimolar amount of surfactant was substituted. 
 
Purification of BiNPs 
A 20 mL aqueous solution of the black BiNPs was diluted in an additional 30 mL 
water and centrifuged at 3.0 krcf for 30 minutes. Following centrifugation, 
particles were dialyzed (SnakeSkin regenerated cellulose dialysis tubing, 
10k MWCO) against electrophoretically pure water to remove excess solvent and 
reaction by-products. Finally the BiNPs were passed through a 450 nm syringe 
filter (Chromafil Xtra PA-45/25 polyamide) and either stored at 4 °C or flash 
frozen on liquid nitrogen and lyophilized.  
 
BiNP Characterization 
TEM: Transmission Electron Microscopy (TEM) was performed on an FEI Tecnai 
F-20 TEM operating at 200 kV. Purified particles were briefly sonicated and then 
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dropcast onto holey carbon Cu supported TEM grids (Ted Pella) and dried at 
100 °C for 1 hour prior to imaging.  For the core size distribution of BiNPs 
synthesized with glucose surfactant at 80 °C, the longest diameter internal to the 
nanocrystal was measured for 1124 particles.  
 SEM: Scanning Electron Microscopy (SEM) was performed on a FEI Sirion XL30 
FEG SEM. Samples were drop-cast onto an aluminum support stub and sputter 
coated with gold (PELCO 91000 Sputter Coater) for 60 sec. 
DLS: Dynamic Light Scattering (DLS) measurements were performed on a 
Horiba LB-550 dynamic light scattering instrument, and an instrumental algorithm 
was used to supply the hydrodynamic number distribution. For measurements, 
freshly syringe filtered samples were dispersed in water and measured at 5 
dilutions to ensure size distributions independent of concentration effects. A 
representative hydrodynamic diameter distribution, as determined by DLS, is 
shown for BiNPs synthesized at 80 °C with glucose surfactant. The same sample 
used to determine core measurements by TEM was used for DLS measurements. 
XRD: Lyophilized BiNPs were pressed onto a glass support slide and X-ray 
diffraction (XRD) data were collected in focused beam (Bragg-Brentano) 
geometry on a Rigaku Ultima IV X-ray diffraction system using graphite 
monochromatized Cu Kα radiation. Scans were performed over the angular 
range 10-70° 2θ at a scan rate of 0.25°/min at room temperature. 
FT-IR: Fourier transform infrared (FT-IR) absorbance spectra were collected on a 
Thermo Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce 
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diamond attenuated total reflectance (ATR) attachment. Aqueous or lyophilized 
BiNPs were drop-cast or pressed with a glass slide onto the ATR crystal to 
deposit sample films for analysis. Glucose solid and liquid PPD were measured 
in their neat forms for comparison by placing them in physical contact with the 
ATR crystal for measurement.  
NMR: Lyophlized BiNPs, glucose or PPD was dissolved in 750 µL D2O 
(Cambridge Isotope Laboratories, 99.9%) and measured on a Bruker 600 MHz-
1H AVANCE-III Nuclear Magnetic Resonance (NMR) spectrometer using a 
standard pulse sequence (Zg30). Spectra were processed using the Bruker 
TopSpin 2.1 software package.  
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES):  
BiNP stocks (5, 10 and 25 µL) were each dissolved in 1 mL of a 1:1 mixture of 
concentrated nitric acid and water. The final volume of each sample was brought 
to 10 mL by addition of deionized water. Elemental analysis was performed using 
ICP-OES (Spectro Genesis ICP) at the Department of Earth and Environmental 
Science, University of Pennsylvania.  For ICP-OES analysis, bismuth analytical 
standards were purchased from Fisher Scientific (Pittsburgh, USA). The 
concentration of bismuth was determined for each sample and then multiplied by 
the dilution factor. The concentrations thus obtained were averaged to give the 
final bismuth concentration of the samples diluted for quantitative CT 
measurements and cell viability assays. 
 
! 108!
Quantitative CT Measurements  
Solutions of bismuth or iodine ranging from 0-100 mM in concentration 
were prepared in triplicate in 1.5 mL micro centrifuge tubes. The samples were 
BiNPs, Bi(NO3)3 or iopamidol, a commercially available iodine-based contrast 
agent; concentration of BiNPs was determined by ICP-OES. The samples were 
placed in a plastic rack and the rack was then wrapped in parafilm. The rack was 
placed on top of another rack and taped to the bottom of a plastic container 24 
cm wide. The container was filled with water to 21 cm in height, to simulate 
attenuation effects of a patient. The preparation of these body phantoms has 
been described previously.(41) 
Each set of samples was scanned in the container with a Siemens 
Definition DS 64-slice clinical CT scanner at 80, 100, 120 and 140 kV and 
300 mA with a matrix size of 512x512, field of view at 37x37 cm and a slice 
thickness of 0.6 cm. The reconstruction kernel used was B30f. Images were 
analyzed using Osirix 64 bit (v3.7.1). The attenuation values, in Hounsfield Units 
(HU) for each sample tube was recorded from three different slices and averaged 
for each concentration. Attenuation rates (HU/mM) reported herein are the 
gradients calculated from of the attenuation (HU) versus concentration (mM) 
plots. 
In vitro cytotoxicity assay: 
Cell culture: J774A.1 murine macrophage cells and HeLa human cervix 
adenocarcinoma cells were purchased from ATCC, Manassas, VA, 
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USA.  J774A.1 cells were maintained in a culture medium of DMEM (Dulbecco's 
Modified Eagle's Medium), while HeLa cells were maintained in EMEM (Eagle's 
Minimum Essential Medium).  In each case the medium was supplemented with 
10% FBS, 45 IU mL−1 penicillin, and 45 IU mL−1 streptomycin. The cells were 
incubated at 37 °C in 5% CO2. Incubations with BiNPs were performed as 
previously described.(42) Briefly, both types of cells were seeded from confluent 
flasks at a 1:1 dilution into six well plates (2 mL/well) and allowed to adhere and 
normalize for 24 hours. The resulting cell monolayers were then washed with 
sterile phosphate buffered saline (PBS).  BiNPs dispersed at concentrations of 0, 
0.10, 0.25, or 0.50 mg/mL in the appropriate cell medium were then incubated 
with the cells. After 1 or 24 hours incubation, the medium was removed and the 
cells were gently washed three times with PBS to remove non-internalized 
nanoparticles. Following incubation and washing, HeLa cells were trypsinized, 
and the J774A.1 cells were collected using cell scrapers. The cells were 
centrifuged at 800 rpm, the supernatant removed and the cell pellets were 
dispersed in 2% v/v aqueous glutaraldehyde. The cells were allowed to settle into 
loosely packed pellets for further quantitative CT attenuation measurements. 
Each experiment was done in triplicate.  
MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) Cell Viability Assay: Cytotoxicity assays were 
performed in 96-well microplates (Nunc, Denmark) seeded with 100 µL of 1 × 105 
cells/mL HeLa or J774A.1 cell suspensions. After 24 hours, cells were washed 
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with PBS and treated with solutions of BiNPs dispersed in complete culture 
medium and incubated at 37 °C in a 5% CO2 humidified incubator. Aqueous 
DMSO (10% v/v) was used as the positive control for both cell lines.  
Assays were carried out according to manufacturer’s instructions. Briefly, 
media were removed after 1 or 24 hours and the cells were washed gently with 
sterile PBS, 100 µL cell culture medium and 20 µL of MTS/ phenazine 
methosulfate solution. After incubation and washing, the absorbance of each well 
was measured in a microplate reader at 490 nm to assess cellular viability. Three 
independent experiments were performed for each exposure concentration and 
the percentage of viable cells was calculated relative to untreated cells. Data are 
presented as mean ± standard deviation (n=3).   
 
Results 
3.4 Synthesis of BiNPs 
For site-directed CT imaging applications, ideal contrast agents will have 
the largest number of highly X-ray attenuating atoms in the smallest volume. For 
nanoparticle XCAs this ratio will be affected not only by the size of the dense 
inorganic X-ray opaque core, but also by the size of its X-ray transparent organic 
surface stabilizing coating. The surface ligands or polymer stabilizers of inorganic 
nanoparticles, which can be covalently bound, electrostatically bound, or 
otherwise physically adsorbed, have been reported to greatly affect the response 
of cells to nanomaterials in vitro (43, 44). Thus the careful selection of all starting 
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materials is important for achieving biologically compatible, high functionality 
XCAs. Furthermore, nanoscale XCAs should be size and morphologically uniform 
to facilitate dose/response predictability, and because large administration 
volumes of contrast material are required for this application, particles should be 
convenient, reproducible and inexpensive to prepare. 
We recently reported an aqueous synthesis method that produced 
dextran-coated BiNPs by NaBH4 reduction of a chemically uncharacterized 
bismuth(III)nitrate suspension in a glycine buffered basic solution.(38) These 
particles, when synthesized at pH 10, have a number of appealing properties, 
such as aqueous synthesis, dense elemental bismuth cores, and a biocompatible 
surface-stabilizing polymer coating. However, these particles were found to have 
a low X-ray opacity by volume and did not provide good qualitative X-ray contrast 
in a concentration range that also maintained good colloidal stability. These 
particles had an average bismuth core diameter of 20 nm by TEM and a 
hydrodynamic diameter of 60 nm by DLS, which, if modeled as three-dimensional 
spheres, indicates that particles are less than 4% bismuth by volume. We 
conclude that poor X-ray opacity of dextran capped BiNPs is due to the large 
surfactant shell relative to the inorganic bismuth core. 
 Substitution of the large molecular weight dextran polymer surfactant with 
lower molecular weight monomeric glucose capping ligand in the previously 
described aqueous synthesis routinely produced particles with poor and 
uncontrolled morphology. We attributed this to the generally poor solubility of 
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bismuth(III) salts in aqueous solution and thus we sought alternate biocompatible 
solvents with greater ability to solvate a bismuth(III) monomer. Good monomer 
solubility should provide better uniformity in particle nucleation and growth, and 
thus result in greater synthetic control over particle size, size distribution and 
morphology. We found that polyalcohol solvents, specifically ethylene glycol, 
glycerol and PPD were capable of forming stable solutions of bismuth(III) ions, 
and concentrations of up to 2 molar bismuth(III) solutions could be produced 
before visible precipitation was observed.  
The “polyol reaction,” which has been used to reduce metal cations to 
elemental nanoparticles through a solvothermal process, has previously been 
used to produce BiNPs in a variety of diol and polyol solvents.(32, 33, 45–47) 
However, in general, we found particles produced by this method to be 
oxidatively unstable when dispersed; particles suspended in water aggregate and 
slowly oxidize to a solid white precipitate. Polyol reactions are poorly 
characterized reduction reactions that occur at elevated temperatures (>150°C) 
and are thought to proceed by reducing metal cations to elemental nanoparticles 
via oxidation of the polyalcohol. We hypothesized that introduction of a 
carbohydrate stabilizing surfactant, such as dextran or glucose, could prevent 
oxidative decomposition of nanomaterials produced in a polyol synthesis. 
However, inclustion of carbohydrate ligands under typical polyol raction 
conditions resulted in a highly polymerized solvent/surfactant/particle aggregate, 
which is difficult to work up further.  
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Scheme 3.1. BiNPs size and morphology dependence on synthetic 
temperature imaged by TEM. Particles synthesized at 60°C, (left) appear 
faceted, crystalline and poly dispersed. Particles synthesized at 80°C, (middle) 
provided the best morphology and monodispersity, while particles synthesized 
at 100°C, (right) appear rounder and with fewer surface facets, but at also 
relatively polydispersed.  
 
 To avoid elevated temperatures leading to carbohydrate decomposition 
under the elevated temperatures necessary for a polyol reaction, (>150°C) we 
thus used a reducing agent to produce BiNPs in glucose saturated PPD at lower 
temperatures (60-100°C). Borane morpholine was chosen as the reducing agent 
for its kinetically slower reactivity, relative to NaBH4, which should aid in size and 
morphology control during growth of BiNPs, and for anticipated ease of removal 
of the expected decomposition products (morpholine and borate) from the 
aqueous BiNPs. We optimized a BiNP synthesis using PPD solvent because of 
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its biocompatibility relative to ethylene glycol, and lower viscosity relative to 
glycerol (31 mPa·s vs 612 mPa·s respectively.)(48, 49) PPD is known to be 
biologically metabolized and is commonly used in food products.(50)  
For BiNP synthesis, bismuth(III) nitrate pentahydrate was dissolved in 
PPD with sonication to produce a fully dissolved bismuth(III) species, and added 
to a solution of PPD saturated with glucose. Addition of borane morpholine at a 
specified synthetic temperature initiated the formation of black, colloidal BiNPs. 
After 60 seconds the entire solution was diluted in ice water to terminate the 
reaction before further workup. Synthetic temperatures were varied between 
60°C and 120°C; generally particles synthesized at higher temperatures (100°C) 
produced morphologically more rounded particles, but with a qualitatively greater 
size distribution, while lower synthetic temperatures (60°C) produced a greater 
percentage of highly faceted particles, but qualitatively lower yields of particles 
were collected during purification (Scheme 3.1). At synthetic temperatures below 
60°C no reaction was observed, and at temperatures above 120°C the 
carbohydrate surfactant began to polymerize. The trade off between morphology, 
size, uniformity and yield was optimized for the scope of this work, and further 
experimentation should result in a more efficient synthesis with lower solvent 
waste.  
To further probe the role glucose plays in particle formation and surface 
stabilization, the effects of alternate surfactants on nanoparticle morphology were 
surveyed. The nanoparticle synthesis can be visually monitored by observing the 
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formation of a black solution of BiNPs from a colorless bismuth(III) solution upon 
addition of reducing agent at temperatures between 60-120°C. In the absence of 
glucose, no color change was observed upon the addition of borane morpholine 
to the bismuth(III) starting material in PPD, and this was attributed to the absence 
of bismuth(0) nanoparticle formation. When sugar alcohols, such as sorbitol and 
xylitol, replaced glucose in the synthesis, again, no particle formation was 
observed. These results suggest that a reducing sugar is necessary for particle 
formation. Fructose (a ketohexose), ribose (an aldopentose), maltose (a reducing 
disaccharide) all enabled the formation and stabilization of BiNPs, albeit the 
morphology of the inorganic core was altered substantially (See Appendix B), 
most likely because the synthesis was optimized for glucose particle formation. 
The detailed mechanism by which reducing sugars are capable of promoting 
surface stabilization these BiNPs is beyond the scope of this study, however we 
anticipate further exploration of this reaction in our ongoing work. 
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Figure 3.1. Size distributions of inorganic core and overall diameter of BiNPs 
synthesized in glucose saturated PPD at 80°C. The longest internal bismuth 
nanocrystal diameter was measured by TEM (A; black bars on histogram). BiNP 
gold sputter coated surfaces were imaged by SEM (B), and the hydrodynamic 
diameter was measured by DLS, (C; grey bars on histogram).  
 
3.5 Characterization of Aqueous BiNP Colloids 
BiNPs synthesized at 80°C appear by TEM imaging to be discrete, 
abundant, highly crystalline, and faceted (Figure 3.1 A and B). Because of the 
anisotropic nanocrystal morphologies observed, a longest diameter (LD) size 
distribution was obtained by manually measuring the longest apparent internal 
distance for >1,000 nanoparticles by TEM imaging. (Figure 3.1 C) The BiNP core 
diameters were found to be 74 ±14 nm. The LD core size distribution is shown 
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(Figure 3.1 C, black histogram) overlaid on a corresponding hydrodynamic 
diameter size distribution measurement obtained by DLS analysis on the same 
colloidal sample (Figure 3.1 C, grey histogram). The average hydrodynamic 
diameter determined by DLS was 86 nm. The SEM image shown, (Figure 3.1 B) 
at the same magnification as the TEM image, (Figure 3.1 A) also shows a similar 
surface to core diameter ratio for these particles.  
 
Figure 3.2. TEM image of particle cores. Nanocrystals are discreet and 
distributed, indicating individual and isolated particles. Powder XRD (inset) of the 
BiNP sample matches elemental bismuth (JCPDS Card No. 00-044-1246). Miller 
indices are shown for each reflection peak. 
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The similarity in the TEM and DLS size distributions indicates that the 
majority of the particle volume is constituted of the inorganic nanocrystal core, 
with only a small portion of the hydrodynamic size attributed to the organic 
surface stabilizing coating. However size distribution data do not take into 
account particle anisotropy, which will affect the inorganic core ratio, but are 
difficult to model for irregular and faceted particles. The 74 nm core to 86 nm 
surface ratio, when modeled in three-dimensional space for volume, indicates 
that BiNPs are greater than 60% inorganic bismuth by volume. This is a 
substantive improvement to our previous synthesized BiNPs that were calculated 
to be 4% inorganic bismuth by volume.(38).  
Elemental bismuth typically crystallizes in the rhombohedral crystal 
system (R–3m) and interestingly we observe multiple nanoparticle morphologies 
by TEM consistent with preferential face growth of rhombohedral nanocrystals 
(Figure 3.2). Triangles, with 60° angles, pseudo cubes with near 90° angles, and 
hexagons with 120° angles are observed in Figure 3.2. The PXRD pattern of the 
BiNPs matches that reported for elemental bismuth (Figure 3.2 inset; JCPDS 
Card No. 00-044-1246), confirming the rhombohedral, elemental bismuth phase 
of the particles, however the pattern does not indicate a preferred orientation 
effects reflected in the calculated vs. experimental peak intensities. While 
preferential face growth of the nanocrystals during synthesis may occur, as 
evidenced by irregular particle morphology, no predominant crystal orientation 
during synthesis or PXRD sample preparation is detected. 
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Figure 3.3. Surface characterization of BiNPs by 1H NMR and FT-IR. 1H NMR 
spectra indicate both PPD (top) and glucose (middle) are present on the 
nanoparticle surface. FT-IR measurements indicate a high degree of peak 
overlap between PPD, glucose and purified particle. Lyophilized BiNPs show a 
marked decrease in absorbance frequencies, suggesting conformational 
restrictions of surfactants on the dried nanoparticle surface.  
 
The identity of BiNP surface ligands was determined by 1H NMR and FT-
IR. The 1H NMR spectrum of washed and dialyzed BiNPs contains peaks from 
both PPD and glucose, which indicates that both solvent and surfactant are 
present on the BiNP surface (Figure 3.3). The 1H NMR spectrum of the BiNPs 
notably contains a peak at δ=1.1 ppm, consistent with methyl protons from PPD, 
and a peak at δ=5.2 ppm which is consistent with a hydrogen atom bonded to the 
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anomeric carbon in glucose. The broad overlapping peaks observed for the 
BiNPs between δ=3-4 ppm are difficult to definitively assign since protons from 
both PPD and glucose are found in this region. While peak broadening in the 
BiNP spectrum may be indicative of a slower tumbling rate of the organic 
molecules in solution when adhered to large inorganic nanoparticles. 
Consistent with the 1H NMR results, the FT-IR spectra has features of 
both from solvent and surfactant, indicating that both are present on the BiNP 
surface. Specifically the peaks clustered around 1100 cm-1 are assigned to C-O 
vibrations. C-C vibration absorbance peaks are predicted around 1000 cm-1, C-H 
stretching around 2900 cm-1 and a broad O-H absorbance is observed between 
4000-3000 cm-1.(51) Washed and purified BiNPs show a markedly different FT-
IR spectrum after lyophalization, with a decreased number of peaks between 
1500-700 cm-1, in addition to the vibrational O-H absorbance. This may be 
attributable to conformational restrictions of the organic surfactants on the BiNP 
surfaces, or perhaps to surface molecule cross-linking, which we hypothesize to 
be the result of a high degree of induced hydrogen bonding that lyophlization 
imparts by removal of water. The degree of hydrogen bonding, indicating the 
degree of macromolecular organization, has been previously examined using FT-
IR spectroscopy to track the degree of crystallinity during cellulose 
hydrolysis.(52) Here, the altered spectrum suggests restricted movements and 
vibrations of the organic shell, which indicate increased hydrogen bonding and 
ordering of carbohydrates on the BiNP surface. 
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3.6 X-ray Contrast and Cytotoxicity Evaluation of Glucose BiNPs 
The X-ray attenuation of BiNPs was measured using a clinical Computed 
Tomography (CT) scanner and particles loaded into micro centrifuge tubes 
submerged in a 21 cm depth water to mimic imaging conditions in a patient. 
Concentrations of bismuth from 0 to 65 mM were measured at 4 commonly used 
X-ray tube voltages, namely 80, 100, 120, and 140 kV, and the CT image 
obtained for the BiNP solutions is shown. (Figure 3.4 A) The X-ray attenuation in 
Hounsfield Attenuation (HU) is plotted as a function of bismuth concentration, 
and shows a linear correlation between bismuth concentration and HU values. 
Figure 3.4 B) The X-ray attenuation of bismuth in the form of aqueous BiNPs, 
relative to that of solvated bismuth(III) nitrate ions and an aqueous iodine 
standard (iopamidol) is also shown (Figure 3.4 C) and was obtained by 
calculating the slope of the attenuation vs. concentration plot for each tube 
voltage. Both forms of bismuth show significantly higher X-ray attenuation relative 
to iodine. Interestingly the iodine attenuation rate decreases with increasing X-ray 
tube voltage, while the bismuth(III) and BiNPs show a relatively voltage 
insensitive attenuation rate, which may be advantageous for using bismuth in 
medical imaging application. We postulate that the slightly higher attenuation 
rates observed for bismuth(III) ions are due to solvent effects; the BiNPs are 
suspended in water and the bismuth(III) ions are suspended in ethylene glycol.  
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Figure 3.4. CT attenuation evaluation of BiNPs. Solutions varying in 
concentration between 1-65 mM bismuth were analyzed by ICP-OES and imaged 
with CT (A). The quantitative attenuation of bismuth in particles as a function of 
X-ray tube voltages (80-140 kV) is reported in HU (B). The rate of attenuation as 
a function of concentration for BiNPs, bismuth(III) ions and iodine were compared 
at different  X-ray tube voltages and are reported in HU/mM (C).  
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Figure 3.5. Uptake of BiNPs in model cell lines. J774A.1 and HeLa cells were 
incubated with BiNPs and collected by centrifugation for CT imaging (A) or 
quantitative attenuation analysis (B). TEM analysis of fixed cells shows that both 
cell types appear to uptake particles. Vessel formation is clearly observed around 
particles for both J774A.1 (C) and HeLa cells (D). 
 
Increased biological compatibility is the primary motivation for 
development of bismuth based XCAs, and as discussed earlier, BiNPs be 
bleared via different biological pathways than renally filtered molecular iodine 
XCAs, which will also result in increases retention and circulation times. BiNPs 
described in this study have a similar pH oxidative decomposition response as 
previously described dextran capped particles,(38)  namely particles are stable in 
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moderately basic phosphate buffered solutions (pH values 8-10) but in acidic (pH 
values less than 7) or extremely basic (pH values greater than 10) particles show 
oxidative decomposition (see Appendix B). The toxicity effects of this pH 
dependent stability will be difficult to predict. On one hand the instability may 
prove advantageous to prevention of bioaccumulation, which is a reported toxicity 
issue for AuNPs used as XCAs, and on the other hand the decomposition of 
BiNPs may release damaging or cyto-toxic bismuth species.  
 Since little is known about the cyto-compatibility of BiNPs, solution 
stability and cellular response (uptake and viability) studies were performed. In 
this study two cell types were evaluated for viability in the presence of the BiNPs. 
HeLa cells were selected for their ubiquitous use in research and murine 
monocyte macrophage cells (J774A.1) were chosen their known ability to 
internalize and uptake nanoscale materials. BiNPs were dispersed in culture 
media (0.1, 0.25, and 0.5 mg/mL) and incubated for 24 hours before collecting by 
centrifugation and washing with clean media. CT imaging of the resulting cell 
pellets shows a substantial increase in attenuation in the macrophage cells 
incubated with BiNPs, and only a slight increase in the attenuation in the HeLa 
cells (Figure 3.5 A). Increased uptake of BiNPs by the macrophage cells appears 
to be concentration dependent, and the X-ray attenuation shown in HU is plotted 
against BiNP incubation concentration. (Figure 3.5 B) Cells were also examined 
by TEM imaging for nanoparticle localization. Fixed macrophage cells show 
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visible formation of phagosomes around BiNPs. (Figure 3.5 C) Engulfment of 
particles by vessel formation is also noted for HeLa cells. (Figure 3.5 D) 
Cell viability was examined using a standard MTS assay that yields 
quantitative information on cellular enzyme activity. (Figure 3.6) After one hour of 
incubation with BiNPs no significant decrease in cellular viability is present for 
either cell type. After 24 hours of incubation with BiNPs, HeLa cells do not show 
a decrease in viability at BiNP concentrations up to 0.5 mg/mL; however 
macrophage cell viability drops, with an apparent LD50 of 50 µg/mL. The 
engulfment and absorption of particles by cells suggests that removal of BiNPs, 
when used as XCAs, will be primarily through the lymphatic system, as these 
particles are expected to be large enough to avoid filtration through the kidneys. 
Decreased macrophage cell viability at these elevated concentrations is 
unsurprising, but does warrant further exploration. The sustained viability of HeLa 
cells in the presence of BiNPs and the sustained viability of the macrophage cells 
at 1 hour time points is suggestive of good biological compatibility. Future in vivo 
studies will further examine biocompatibility and BiNP fate (i.e. clearance) in 
addition to characterization of the BiNP decomposition products.  
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Figure 3.6. Viability of HeLa and J774.A cells incubated with BiNPs. Particle 
concentrations of 6.1 µg/mL to 0.5 mg/mL were incubated with cells and viability 
of cell cultures at 1 hour were assessed relative to unexposed cells. After a 24 
hour incubation, HeLa cells show no decrease in cell viability at the highest BiNP 
concentrations measured and J774A.1 cells show an apparent LD50 around 
50 µg/mL. 10% v/v aqueous DMSO was used as a positive control for both cell 
lines. 
 
3.7 Conclusion: 
Nanoscale XCAs have been well advocated for their many potential 
advantages, including potential alternate biological clearance routes and longer 
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circulation times relative to molecular XCAs, which may enable blood pool 
imaging, site directed imaging and decreased administration volumes. BiNPs 
relative to previously demonstrated AuNPs XCAs are less oxidatively stable and 
higher in atomic number, which should decrease bioaccumulation while providing 
increase X-ray contrast. Here we describe and characterize a novel synthetic 
strategy for the production of stable BiNPs using PPD as an inexpensive 
biologically compatible and highly coordinating solvent, coupled with an 
inexpensive glucose surfactant layer. Particles have a large inorganic elemental 
bismuth core relative to the total hydrodynamic size and 1H NMR and FT-IR both 
suggest solvent and surfactant are present on the particle surface. Particles show 
a high X-ray attenuation by CT imaging, and good preliminary biological 
compatibility studies. These data suggest this will be a new and highly improved 
research level nanoXCA.  
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Chapter 4 – Inexpensive, Aerobic Synthesis of Hydrophobic Organoamine 
Bismuth Nanoparticles 
Adapted from:  
 Manuscript in Preparation by: Anna L. Brown, William Alexander Merrill, 
 Rebecca Chitkowski and Andrea M. Goforth 
 
4.1 Abstract 
 We report a simple aerobic synthetic method for the production of size 
and morphologically uniform bismuth nanoparticles. Spherical bismuth particles 
result from the reduction of dissolved bismuth triiodide in a 
hexadecylamine/hexadecane solvent mixture at 200 °C; all reagents are 
commercially available and inexpensive. The hexadecylamine serves as solvent, 
reducing agent, and surface stabilizing ligand, and hexadecane serves as a co-
solvent. The organoamine-coated bismuth nanoparticles were characterized by 
TEM, SEM, and FT-IR spectroscopy. 
 
4.2 Introduction to Bismuth Nanoparticle Organoamine Synthesis 
 The potential uses and applications of nanomaterials are inspiring new 
fields in science, but testing and exploiting these new materials are often 
inhibited by synthetic limitations. Bismuth nanoparticles hold great promise for 
future technologies; as examples the bulk semi-metalloid element has an altered 
electrical conductivity on its nanoscale surface, which is interesting for 
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thermoelectric materials(1–5) and both high atomic number and biocompatibility 
for medical X-ray attenuation applications.(6, 7)  
 Synthesis of morphologically uniform bismuth nanoparticles by 
previously published methods have generally used air-sensitive precursors, 
specifically bismuth(III) trimethylsilylamide.(8–10) The advantage of this 
precursor as a bismuth source for nanoparticle synthesis is its good solubility in 
nonpolar solvents, which facilitates the solubility of discrete ions for reduction, 
nucleation, and growth of homogenous particles. However air sensitivity makes 
preparations using this precursor confined to well equipped and specialized 
laboratories. Furthermore high time and reagent cost and low particle yield from 
these specialized precursors can make further application focused 
experimentation financially limiting. Thus a molecular bismuth precursor which is 
aerobically stable, inexpensive, and soluble for building nanoparticles is 
appealing for both basic and applied research. Unfortunately the generally poor 
solubility of bismuth(III) compounds makes finding a precursor for nanoparticle 
synthesis difficult. Bismuth readily forms polynuclear ionic species and insoluble 
precipitates with a wide range of halides and oxides,(11) which, if used in 
nanoparticle synthesis, can lead to inhomogeneity in nanocrystal morphology. In 
order to develop a versatile bismuth nanoparticle synthesis using a low cost, 
soluble precursor, we adopted the Osterloh organoamine method for synthesis of 
noble metal nanoparticles,(12) using an iodobismuth precursor and 
hexadecylamine as co-solvent, surfactant, and reducing agent. Iodobismuth 
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anions have been synthesized under a variety of conditions and have variable 
stoichometry, but can exist as discrete and isolatable clusters.(13, 14)  
 As bismuth structures under 50 nm are thought to undergo a semi-
metal to metal transition, the electronic state and atomic arrangement at the 
bismuth nano surface are complicated but have a number of applications, most 
notably for thermoelectric materials.(15) Thus a synthetic method that yields 
particles with selected ligands, or available for ligand exchange,(4, 10) should 
enable a further understanding of bismuth surface electronics. We posit that 
bismuth nanoparticle surfaces are electron deficient because of the termination of 
the crystal lattice, but are not overall charged. Thus dative bond stabilization of 
these surfaces from an electron dense organic molecule with a neutral charge 
should be favored. We use hexadecylamine as a high boiling solvent that is both 
hydrophobic and has a primary amine available for reduction of the bismuth 
cations. The amine additionally acts as an electron-dense, surface-stabilizing 
ligand. Particles synthesized by this method are relatively uniform and should 
enable further experimentation for bismuth surface electronic studies and ligand 
exchange .  
 
4.3 Synthesis and Methods 
 In order to form a soluble iodobismuth precursor, BiI3 (2.5 mg/mL) in 
hexadecylamine was heated at 100 ºC for 1 hour to yield an optically clear, bright 
orange solution. To synthesize nanoparticles, 4.5 mL of hexadecylamine, or a 
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mixture of hexadecylamine and hexadecane (1:1 or 1:3), were heated together to 
200 ºC in a beaker submerged in a hot oil bath. Six micromoles of the 
iodobismuth precursor (500 µL) was added to this solution with rapid stirring and 
the solution darkened from a light amber to a dark red and finally black. Particles 
were allowed to grow and stabilize for 5 minutes at synthetic temperature. To 
form spherical particles, solutions were rapidly cooled by removing the beaker 
from the hot oil bath and adding 15 mL of 4°C toluene. To form highly faceted 
hexagons and nanostars, 500 µL of a 5 mg/mL BiI3 bismuthiodo cluster prepared 
as described above was reacted with 4.5 mL hexadecylamine (hexagons) or 
281 µL hexadecylamine and 4.2 mL hexadecane (nanostars) at 200 ºC for 10 
minutes. For hexagon synthesis, the reaction solution was removed from heat 
and allowed to cool to room temperature without stirring. Nanostar morphologies 
were obtained by removing an aliquot of the reaction solution in a glass Pasteur 
pipette and immersing the solution into iced toluene.  
 All particle solutions were then centrifuged at 4.4 kRPM for 20 min and 
twice washed in 3 mL cyclohexane followed by brief sonication to disperse the 
particles and re-collected by centrifugation to remove the other organic 
byproducts of the reduction. Particles were either air dried or resuspended in 
cyclohexane for storage. 
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TEM  
Transmission Electron Microscopy (TEM) was performed on an FEI Tecnai F-20 
TEM operating at 200 kV. Particles suspended in cyclohexane were briefly 
sonicated and dropcast onto holey carbon Cu supported TEM grids (Ted Pella) 
and dried at 150 °C for greater than 2 hours prior to imaging.   
 
SEM 
Particles suspended in cyclohexane were dropcast on aluminum SEM stubs and 
allowed to air dry in layers. Stubs were sputter coated with gold (PELCO 91000 
Sputter Coater) for 40 seconds, and imaged on an FEI Sirion XL30 FEG SEM at 
3 keV.  
 
FT-IR  
Fourier transform infrared (FT-IR) spectroscopy was performed on a Thermo 
Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce 
diamond ATR attachment. For analysis, particles were suspended in 
cyclohexane, dropped onto the ATR crystal, and solvent was evaporated as 
necessary using a heat gun. 
 
4.4 Results and Discussion 
 Bismuth nanoparticles were synthesized by a thermal reduction of 
bismuth iodide in the presence of hexadecylamine and hexadecane. Previous 
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reports of oleylamine as a solvent/reducing agent/surfactant for the synthesis of 
nanoparticles have been reported,(16–19) but the cost limitations for large 
quantities of high purity oleylamine for synthesis led us to explore alternative 
organoamines. Hexadecylamine is structurally similar to oleylamine, and 
importantly has a similarly high boiling port (330 ºC vs 364 ºC, respectively) that 
enables an ambient pressure and high temperature synthesis. However 
hexadecylamine is synthetically derived which allows reagents at higher 
purification and a lower cost to be available. Hexadecylamine is a solid at room 
temperature (mp. 45 ºC) and this makes laboratory work more difficult, but 
inconsistent impurities and the high cost of oleylamine outweigh its synthetic 
ease of use. 
 
 BiI3 was experimentally chosen as a bismuth source because of its 
ability to dissolve and form optically clear suspended solutions in primary amine 
 
Figure 4.1. Bismuth particles synthesized by hot injection of iodobismuth 
precursor into neat hexadecylamine (A) 1:1 (B) and 1:3 (C) 
hexadecylamine:hexadecane. All scale bars represent 500 nm. 
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solvents. While the bismuth source was not characterized, a visible color shift 
from the solid black BiI3 to a bright orange solution was observed, consistent with 
the formation of soluble iodobismuth clusters. BiI3 was stirred in hexadecylamine 
(2.5 mg/mL or 5 mg/mL) at 100 ºC for over an hour prior to particle synthesis to 
encourage equilibrium and homogeneity of the bismuth source. This solution was 
then added to a hot (200 ºC) solution of hexadecylamine or hexadecylamine and 
hexadecane. The rapid onset of bismuth reduction, which, coupled with a dilution 
of the bismuth source, encouraged the growth and stabilization of small, relatively 
uniform, elemental bismuth particles. When particles were grown in only 
hexadecylamine, larger and more irregular morphologies were observed (Figure 
4.1 A) Particles grown in mixtures of hexadecane and hexadecylamine show 
smaller and more uniform size distributions, regardless of the ratio of solvents 
(Figure 4. 1 B and C.) This phenomenon can be explained by the higher degree 
of solvent organization that should take place in solution and on the surface of 
the growing particles when hexadecane is present in solution. In this case, a 
continuous phase of hydrophobic solvent should force hexadecylamine to form 
reverse micelles around developing particles. This would isolate particles from 
growth, ripening, or fusion and would explain the higher particle homogeneity 
observed. Particles synthesized in neat hexadecylamine appear larger and more 
irregular, which suggests a higher rate of ripening or fusion during synthesis in 
the absence of a hydrophobic barrier. 
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Figure 4.2. Bismuth particles synthesized in a 1:1 
hexadecane:hexadecylamine mixture. Particles show lattice fringes with an 
average d-spacing of 3.2 Å, consistent with the (012) plane of rhombohedral 
bismuth metal (top left) and a relatively spherical morphology with an 
average diameter of 41 ± 7 nm (n=707).   
  
 Transmission Electron Microscopy (TEM) studies revealed spherical 
bismuth nanoparticles 41 ± 7 nm in diameter (Figure 4.2). Lattice fringes of 3.3 Å, 
which indicated the theoretical (012) d-spacing of the rhombohedral (R–3m) 
phase of crystalline bismuth, were observed in several particles at high 
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magnification. Particles show some long-range organization and packing, 
especially by SEM (Figure 4.3). When colloid solutions were measured by 
Dynamic Light Scattering (DLS), particles had large and irregular (>1 um) 
hydrodynamic sizes which suggests that particles in solution self-organize or 
flocculate.  
 
Figure 4.3. SEM images of bismuth particles synthesized in 
hexadecylamine and hexadecane. Particles are highly aggregated and 
show some degree of self-organization.   
 
 Because the particles were synthesized at very high temperatures, 
above the expected melting temperature of bismuth nanoparticles(20–22), the 
cooling rate and environment after synthesis should affect the morphology of the 
final nanocrystal. Allowing solutions to sit at synthetic temperatures in the 
absence of vigorous stirring, or cooling the particles at relatively slow rates, 
particularly highly concentrated synthetic solutions, enabled the growth of highly 
faceted and irregular nanocrystals. Figure 4.4 shows representative images of 
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particle morphologies obtained when cooling rates were relatively slow. To form 
the homogeneous and rounded nanocrystals, shown in Figure 4.2, after a 5 
minute synthesis at 200 ºC, particles were rapidly cooled by diluting the synthetic 
solution in iced toluene.  
   
 FT-IR of particles suggests the organic particle surface stabilizer is 
primarily hexadecylamine. The major FT-IR absorbance signature for 
hexadecylamine is evident on the bismuth nanoparticle surface. A pair of 
absorbance peaks around 3300 cm-1 from symmetric and asymmetric νN–H 
stretches of the terminal –NH2 group on the ligand would indicate either a dative 
 
Figure 4.4. Representative morphologies of bismuth nanocrystals obtained 
when synthetic solutions at reaction temperature were not rapidly cooled. 
Hexagonal shapes (left), with 120º facet angles were the most commonly 
observed morphologies. Hexagonal nanostars (right) are a novel bismuth 
nanocrystal morphology. 
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R–(H)2N:  Bi coordination interaction or a R–(H)N–Bi (amidometal) bond. 
Neither stretch is indistinguishable from the background, and further 
characterization will be necessary to elucidate the binding mode. However the 
presence of hexadecylamine on the surface of the particles, which have been 
extensively washed, suggests a chemical bond between the amine and the 
bismuth particle.  
 
Figure 4.5. FT-IR spectrum of dried bismuth nanoparticles (top, black), 
and of neat hexadecylamine (bottom, red).  
 
Thus while the nature of the amine-bismuth interaction is not elucidated by the 
FT-IR profile, it can be concluded that there is a stabilizing chemical or physical 
interaction by the primary amine on the bismuth surface. 
                                                                                                       
4.5 Conclusion 
 We report the synthesis of 41 ± 7 nm bismuth nanoparticles from BiI3 in 
a hexadecylamine and hexadecane solution at 200 °C. Addition of hexadecane to 
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the reaction solution yields smaller and more homogenous particles, and a rapid 
cooling of particles is necessary to yield rounded uniform particles. Particles 
show some degree of self-organization when imaged by SEM, and have 
hexadecylamine on the surface, as characterized by FT-IR. We anticipate these 
particles to be useful in experimental and practical applications where synthesis 
of bismuth nanoparticles using expensive reagents or laboratory equipment may 
be cost prohibitive. 
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Chapter 5 – Highly X-ray Opaque Polymer/Bismuth Microparticle 
Composite Materials 
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5.1 Abstract 
 The synthesis of bismuth microparticles and their incorporation into 
polymeric matrices for the development of highly X-ray opaque composite 
materials, is described. Particles were fabricated by ball milling bulk bismuth in a 
coordinating solvent, such as dihydroxy acetone, 1-pentene, and styrene, and 
then mixed with liquid polymers such as silicone, polyurethane, polystyrene, and 
latex to form composites. Composite materials are shown to be highly X-ray 
attenuating and can be molded to make X-ray opaque ribbons for surgical 
sponge markers, inks, and other items with specified physical properties. 
 
5.2 Introduction to X-ray Opaque Composite Materials 
 X-ray photography is a ubiquitous technique in modern medicine with the 
ability to noninvasively image certain internal biological structures and to survey 
for foreign objects. In efforts to avoid surgical retained foreign objects (RFO) 
some medical tools and devices have been specifically impregnated or tagged 
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with heavy atomic number elements so that they can be easily located inside a 
patient by X-ray imaging. Surgical sponge retentions account for greater than half 
of all RFOs because of their small size, frequent use and the difficulty in visually 
detecting soiled sponges against a morphologically similar anatomical 
background.(1) Surgical items that frequently become RFOs, such as sponges 
and other items composed of low atomic number elements, are the most 
commonly tagged or modified for X-ray imaging. The addition of an X-ray opaque 
BaSO4 based composite material molded as a thread or ribbon and sewn into a 
surgical sponge was developed decades ago and are commonly used in the US, 
but poor X-ray contrast makes them difficult for radiological detection, even under 
ideal imaging conditions.(2) More recently, Radio Frequency Identification (RFID) 
tagged sponges and operating room detectors have been introduced, but the 
high cost and required changes to operating room protocols have slowed 
embrace of RFID monitoring for RFO.(3) Unlike RFID scanning, X-ray imaging of 
patients prior to surgical wound closure is common practice; thus an inexpensive 
X-ray contrast marker with greater X-ray opacity than markers currently available 
would make retained surgical sponges easier to image and would be an optimal 
solution to RFO detection prior to surgical wound closure. The development of 
technologies for detection of surgical implements prior to closure of a surgical 
wound has been prompted by the high likelihood of further medical complications 
arising from RFOs, including local and systemic infections, and additional 
corrective surgical procedures that often result in lawsuits.  
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While surgical sponges are the most likely to objects to become ROF, 
other medical devices or implements could benefit from a highly X-ray opaque 
contrast material additive. Embedding highly X-ray attenuating materials into 
items used in invasive treatments, or to track implant devices, would enable X-
ray imaging of materials which are normally X-ray transparent, such as plastics. 
Fluoroscopy, the technique whereby continuous X-ray images are collected to 
obtain dynamic imaging information of internal structures, would benefit from the 
incorporation of highly X-ray opaque material or tags by enabling low X-ray 
attenuating implements to be used and imaged by the physician during a 
procedure. This could include polymer based implants, catheters, stents, picc 
lines and equipment that may break or fragment during a procedure.(4) In a few 
specific applications highly radiopaque, yet mechanically flexible, medical 
implements could be useful. This could include replacements for the relatively 
expensive silver guide wires used in intra-arterial procedures, such as 
angioplasty.(5) Furthermore improved, more flexible, durable and thinner X-ray 
shielding materials could be generated from the materials described in this 
chapter. Most X-ray shielding materials are composed of lead salts because this 
element has a high atomic number and is extremely low cost. However, the 
inherent toxicity of lead inhibits its use in medical applications where a device 
may have intimate contact with a patient or medical personnel. Thus shielding 
devices used in a medical setting require protection barriers, such as 
heavyweight vinyl between the shielding material and environment. An X-ray 
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attenuating material that does not have these toxicity concerns would not require 
the protection barriers.  
Bismuth has an X-ray attenuation profile similar to lead, but the well-
known biological compatibility of this element eliminates a number of health 
concerns that arise from the use of lead. Because contact with lead is generally 
considered unsafe it cannot be used as an X-ray contrast marker for applications 
where routine or accidental contact may occur. Elements on the periodic table 
with large atomic numbers, and thus a high X-ray attenuation, are generally toxic, 
are prohibitively expensive, or both. Gold is a heavy, dense element and 
exploration of gold nanoparticles as intravenous X-ray contrast agents is an 
active area of research, but the price of gold (currently approx. $8,850 per mol) is 
prohibitively expensive for this application. Platinum has a similar price per mole. 
Other dense elements, such as thallium, iridium and osmium are also 
prohibitively expensive, and are additionally extremely toxic.  
To produce a material with the highest X-ray attenuating potential in the 
smallest volume, the elemental form of the attenuating element will be required. 
Thus sheets of the elemental material will provide the highest X-ray attenuation 
per volume and weight. Because the medical applications described above will 
require a material which can be molded into a wide range of shapes and have a 
degree flexibility in the final product, microparticles of highly X-ray attenuating 
material embedded in a polymer matrix should impart both desired properties. 
Bismuth molecular species and nanoparticles embedded in a polymer matrix 
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could produce materials with a high X-ray attenuation as well, but the increased 
surface area of the smaller atoms, clusters or nanopartucles would require larger 
amounts of polymeric material relative to the number of X-ray attenuating atoms. 
Therefore, bismuth microparticle composites should require less polymeric 
material per functional atom, which will reduce the overall weight and volume of 
the contrast or shielding material. The development of a thinner, lighter and low 
toxicity composite material will enable development of a wide range of novel or 
improved medical devices which are highly X-ray attenuating or shielding. 
 
Scheme 5.1. Bismuth particle composite materials composed of a 
polymer matrix and bismuth particles that have been coated in an 
appropriate surfactant for matrix miscibility. 
 
A bismuth microparticle additive for comoposite materials will need to be 
inexpensive to produce and should be miscible in a variety of solvents to enable 
incorporation in numerous types of polymeric matrices. The medical applications 
of a material possessing the properties of highly X-ray attenuating, moldable, 
flexible, non-toxic and inexpensive are numerous. In this research, material 
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optimization and a performance assessment was focused on the development of 
a surgical sponge marker based on market evaluation and suggestions of a 
commercialization opportunity report done by the Winter 2011 Engineering and 
Technology Management New Venture Management class (ETM 562/662). In 
addition to the surgical sponge markers, other composite materials and devices 
and X-ray opaque inks discussed in this chapter were developed and 
incorporated in a patent application (U.S. Provisional Application No. 61/493,913, 
filed June 6, 2011). A shielding and attenuation evaluation of surgical sponge 
prototype materials was also performed, and used to calculate the theoretical 
thicknesses of a bismuth microparticle shielding device. 
 
5.3 Methods 
Bismuth Particle Preparation 
 Bismuth powders were prepared by ball milling bulk bismuth and a solvent 
with or without an additional surfactant in a stainless steel grinding vial with 
tungsten carbide balls for 20 minutes. In a typical preparation 5 g of elemental 
bismuth (Rotometals, Bismuth Ingot 99.99% pure) was milled with 5 g solid 
surfactant and in certain cases 10 mL of an appropriate solvent (such as 1,2 
propane diol or 1-pentene). To prepare hydrophobic particles, 10 mL of 1-
pentene (Acros Organics, 97%) was used, with no additional surfactant added. 
For the synthesis of hydrophilic particles, 10 mL of 1,2-propane diol (Acros 
Organics 99%, Extra Pure) and 5 g dihydroxyacetone (MP Biomedicals) was 
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used. Styrene capped particles were milled in 10 mL styrene (Acros, 99% 
stabilized). The particles, suspended in their milling solvents, were either sieved 
(Fisher Scientific Test Sieve no. 325, 45 µm) and washed with an appropriate 
solvent and collected by centrifugation or washed, collected, dried, then ground 
to a powder and sieved.  
 
Matrix Incorporation 
 Particles were incorporated into a variety of polymer matrices, including 
silicone (GE 100% silicone), polyurethane (VytaFlex 20 urethane), Latex (n-
heptane, natural rubber latex, Ross acid-free rubber cement) polystyrene 
(commercial packing material) and dextran (Fisher, 86 kDA) composite materials. 
In a typical preparation, the dried bismuth powder was weighed, the liquid matrix 
was added and the weight of both matrix and powder were recorded. If the liquid 
weight of the matrix changed upon drying (as in the case of silicone) this was 
considered and incorporated into the calculation. The liquid unset polymers and 
the bismuth microparticles were mixed, in some cases with the addition of a 
carrier solvent such as pentane for silicone, or in the case of polystyrene, toluene 
(ChemProducts), and water in the case of dextran. No carrier solvent was used in 
preparation of polyurethane composites. The composites were either allowed to 
air-dry, or, in the case of the polyurethane composites, were placed under 
vacuum for 5 minutes to remove air bubbles before pressing into a PTFE mold. 
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The final composites contained the homogenously distributed bismuth micro 
particles as a known weight percent of the dried material. 
 
SEM Imaging 
 SEM imaging of particles and composites was done on a FEI Sirion XL30 
FEG SEM. Powder samples were mounted on SEM stubs with adhesive, or 
composite materials were thinly sliced with a razor and mounted on adhesive. All 
samples were sputter coated with gold (PELCO 91000 Sputter Coater) for 60 
sec.  
 
5.4 Results and Discussion 
Production of large quantities of inexpensive micronparticles was 
undertaken using top down protocol. In this process, a chunk of elemental 
bismuth is ball milled in an excess of coordinating surfactant to produce a wide 
range of particle sizes. The resultant particle mixture is washed in an appropriate 
solvent and collected by centrifugation. Particles are size selected with mesh 
sieves or syringe filters. These particles generally retain the miscibility of the 
coordinating solvent, thus enabling synthesis of particles which can be surface 
tailored to be dispersed in a wide range of matrices. Coordinating solvents were 
compared for surface sorption on milled bismuth and solvent choice was 
assessed for morphology effects on particles. Hydrophobic and hydrophilic 
particles were synthesized. These particles were embedded in different matrix 
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polymers (such as silicone, polyurethane, latex and styrene) for demonstration of 
application and X-ray opacity studies.  
 
Figure 5.1. Bimsuth particle miscibility illustrated 
by solvent separation. Particles milled in 
dihydroxy acetone (A) or in 1-pentene (B), show 
solubility preference for water or hexanes 
respectively. 
 
Aqueous Particles 
Synthesis of particles soluble in water was 
undertaken by utilizing knowledge of suitable 
surfactants from previous nanoparticle synthesis 
experiments. As carbonyls had previously shown 
highly stabilizing to bismuth particle surfaces, 
dihydroxyacetone (DHA, Scheme 2) was milled with bismuth to produce particles 
with alcohol surface functionalities. These particles proved hydrophilic and were 
washed multiple times in water to remove excess surfactants and collected by 
 
Scheme 5.2. Structure 
of dihydroxy acetone 
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centrifugation. (Figure 5.2) Particles were then dried at 140 °C in a ceramic 
crucible for greater than 2 hours and ground with a pestle. The dried powder was 
passed through a 45 µm mesh sieve and stored in a glass jar at room 
temperature. Larger particles which did not pass through the sieve were recycled 
and processed as bulk bismuth. 
 
Figure 5.2. Illustration of microparticle synthesis, purification, size selection. 
SEM image insert shows dry sieved particles. 
 
The primary application recommended by the Winter 2011 technology 
venture class was to develop a better radiopaque surgical sponge marker. The 
current commercially used makers are composed of a polymer, reported to be a 
composite material of polyvinylchloride, 60-83% barium sulfate and other 
plasticizers and colorants. (Tariff No.: 2833.27.0000) Sponge markers from a 
laparotomy sponge produced by Medline Industries were collected and used as a 
reference for market available radiopaque surgical sponge markers. A cross 
sections of these markers was measured by SEM and found to be approximately 
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400 µm. To create a marker with comparable dimensions, but with increased 
contrast additive weight ratios, polyurethane was used as the matrix polymer 
because of its high strength. Dry sieved DHA capped particles were measured by 
weight and an appropriate ratio of unpolymerized polyurethane solution was 
added. Bismuth particles and polymer solution were mixed and scooped onto a 
flat PTFE surface and placed in a vacuum desiccator to remove gas bubbles. 
Spacers of desired thickness (for 400 µm thickness, 2 widths lab tape and 3 
widths scotch tape) were placed proximal to particle mixture and a second piece 
of flat PTFE was placed on top of solution and clamped. Composite material was 
allowed to polymerize over night and heated (125°C, 1 hour) after removal from 
mold.  Shown in Figure 5. 3 is an SEM images of the synthesized particles 
(Figure 5.3 A) and a schematic of their incorporation into a lquid polymeric 
material (Figure 5.3 B.) The resultant composite materials produced show visable 
particles encased in a polymer when imaged by SEM (Figure 5.3 C-F.) 
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Figure 5.3. Polyurethane and commercially available X-ray opaque sponge 
markers. Dried DHA >45 µm sieved particles (A) were mixed with liquid 
polyurethane and pressed between sheets of PTFE with spacers of a designated 
thickness (B). A Medline X-ray opaque sponge marker was imaged by SEM next 
to composites made of 85, 60, 40, and 20 % bismuth particles by weight (C, 
cross sections in order mentioned from upper left corner.)  Marker composed of 
85% by weight bismuth clearly shows particles embedded throughout polymer 
matrix (E and F). Medline marker shows a much smoother and more uniform 
appearance, presumably due to the smaller size of BaSO4 salt particles (D). 
 
To compare attenuation of the commercially available surgical sponge 
markers (Medline) to the bismuth composite markers, X-ray attenuation was 
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performed by Health Physics Northwest (HPNW) and is shown in Figure 5.4. The 
Medline markers show a similar attenuation profile to bismuth marker with 40 % 
by weight loading. Interestingly, the attenuation for the 40 % weight loaded 
bismuth marker dropped relative to the Medline marker at higher X-ray energies 
(>100 keV) consistent with a theoretical drop in attenuation at energies above the 
k-edge of bismuth at 90 keV.(6) Measurements by HPNW included thickness 
analysis using a Peacock Dial Thickness Gauge, Model H and measured a 0.56, 
0.55, 0.51 and 0.64 mm thickness for the Medline, 40, 60 and 85 % by weight 
bismuth markers respectively. This was inconsistent with SEM measurements of 
the markers, which showed a thickness of approximately 400 µm. (Figure 5.3 C). 
The 85% bismuth marker had an lead equivalent X-ray attenuation of 0.21 
mm. X-ray aprons used in medical facilities typically have a 0.5 mm lead 
equivalent attenuation(7), which would indicate a 1.2 mm thick sheet of the 85% 
bismuth composite material would provide similar radiation protection, if used as  
a shielding material.  
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Figure 5.4. X-ray attenuation of loaded surgical sponge markers. 
Polyurethane composite materials were made with DHA capped bismuth 
particles (<45 µm) embedded in a polyurethane matrix, and pressed to 
approximately 400 µm. 40, 60 and 85% bismuth particle composite materials 
by weight were compared to a standard Medline surgical sponge marker. The 
85% by weight composite sample had an attenuation equivalent to 200 µm of 
lead.  
 
The 60% bismuth composite material would need to be 3.125 mm. The primary 
advantage of these bismuth composite materials over a lead based shielding 
material would be no additional layer separating the patient from the attenuating 
material, commonly polyvinyl chloride in lead based shields. This would enable 
the manufacturing of lighter weight and substantially thinner personal radiation 
shielding equipment. These could be manufactured into a variety of protective 
products, such as gloves. 
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Other applications, and demonstrations of applications, of hydrophilic 
particles have included dextran polymer matrices particle liquids, which are 
flowable and water soluble and dry to form hard “discs” of bismuth particles 
illustrated in Figure 5.5. This method was also used to form water-soluble inks, 
which are then highly radiopaque, and can be easily re-dissolved in water for 
removal and recycled. As latex is common material used in a number of medical 
applications, latex suspensions of aqueous phase particles were made and dried 
into rubber sheets. (Figure 5.6) The latex composite materials were somewhat 
 
Figure 5.5. Hydrophilic particles embedded in a dextran polymer matrix 
and dried into a small disc. SEM images show aggregated particles held 
together at a high density, and smooth surface on top and bottom of the 
disc. Photograph of broken disc next to a dime is show for size 
comparison. 
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elastic, however they did show substantially decreased structural integrity over 
pure latex, possibly due to poor miscibility between the matrix and the particles. 
 
Figure 5.6. Latex composite materials. DHA capped particles were incorporated 
into a latex matrix. 
 
 
 
Hydrophobic Particles 
 A number of plastics and rubbers used in medical items are formed using 
precursors which are soluble in organic solvents and thus a particle miscible in 
organic solvents was synthesized. 1-pentene was chosen as a surface sorbent 
due to high volatility and electron density at one end of the molecule. Comparison 
of surface morphologies of particles synthesized in 1-pentene and pentane 
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suggest the double bond served as a source of electron density to surface 
stabilize particles during milling and prevent re-compacting of smaller particles 
into larger, polycrystalline particles. (Figure 5.7) 
 
 
 
Figure 5.7. SEM images of bismuth micron particles made by ball milling 
bulk bismuth in 1-pentene (left) and pentane (right). Particle synthesized in 
non-surface adsorbing pentane appear to recombine and pack into 
aggregate particles, possibly due to instability of the freshly exposed 
bismuth surface. 
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Incorporation of hydrophobic particles into silicone matrixes was used as 
initial illustrative proof of principal for surgical sponge markers as industrial grade 
silicone is inexpensive and easily molded and polymerized. Experiments using 
hydrophobic particles embedded in silicone were successful in that number of 
highly attenuating markers were synthesized, but difficulties with decreased 
marker attenuation arising from the formation of bubbles in the silicone, in 
conjunction with a highly reduced structural integrity of the silicone composite 
 
Figure 5.8. Silicone and hydrophobic bismuth particle composite materials. 
A silicone composite marker shows substantially enhanced attenuation over 
a bovine T-bone by X-ray (upper left). Particles were synthesized with 1-
pentene (lower left) and embedded in a silicone matrix (right top and 
bottom).  
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materials, lead us to abandon further development of silicone based sponge 
markers in favor of polyurethane based markers.  
 
Styrene based particle inks 
 Styrene capped particles were synthesized and used to make polystyrene 
composite materials and polystyrene inks. For this application, styrene capped 
particles were incorporated into a solution of liquid polystyrene solvated in 
toluene. These inks could be stored in an air tight pasteur pipette pen and used 
to write on a variety of surfaces, or dried into brittle shapes. Illustrative use of 
these inks is shown in Figure 5.9, where particles in polystyrene (left) were used 
to trace the PSU logo (top right) and an X-ray image of the ink on top of a 
phantom of a hand shows high X-ray attenuation (lower right.) 
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Figure 5.9. Illustrative use of styrene inks. Styrene milled 
particles with polystyrene and carried in toluene used as an 
ink. SEM images of particle ink (left), light photograph of ink 
(top right) and X-ray image of ink with a hand phantom 
(bottom right). 
 
 
 
5.5 Conclusions 
 We demonstrate the use of inexpensively synthesized bismuth 
microparticles embedded in polymers as highly X-ray opaque contrast materials. 
The synthesis of these microparticles by ball-milling bulk bismuth in a 
coordinating solvent is a novel, but highly versatile method for producing surface 
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functionalized bismuth particles. Without a surface coordinating solvent these 
particle recombine into polycrystalline aggregates. Hydrophobic, hydrophilic and 
cyclo-aromatic surface functionalized particles were synthesized and embedded 
in a variety of polymer matrixes for application illustrations.   
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Appendix A - Synthesis of Ethylene Glycol and Glucose Bismuth 
Nanoparticles and Applications as X-ray Opaque Inks 
 
 Synthesis of bismuth nanoparticles in ethylene glycol with glucose as a 
surfactant yielded nanocrystals of distinct morphology and were used as a 
flowable X-ray attenuating inks. Bismuth nitrate (500 µL of 1 M) dissolved in 
ethylene glycol (0.5 mM) was mixed with with 3.3 g glucose in 4.5 mL ethylene 
glycol and brought to specified synthetic temperature (75-115 °C). Borane 
trimethylamine (BTMA) solution (1.5 mM, 1.5 mL of a 1 M solution) melted in 
ethylene glycol (ca. 50 °C) was added to induce nanocrystal growth. Particles 
were grown for 20 second and then poured onto iced water, collected by 
centrifugation and washed in ethanol and water. For synthesis in water, reduction 
took place at 50 °C. Particles were suspended in water and dropcast on holey 
carbon copper support TEM grids for analysis. For XRD analysis particles were 
dried in films on glass microscope slides. A large particle preparation consisting 
of 15.4 g Bi(NO3)3-5H2O and 31.5 g glucose mixed in 350 mL ethylene glycol 
and heated to 90-95 °C were reacted with 7.1 g BTMA dissolved in 100 mL 
ethylene glycol for 20 seconds before quenching on ice. Particles were cleaned 
as previously described and were prepared for use as X-ray opaque ink. Particles 
were suspended in water solution and using a micropipette drawn onto and air 
dried on a sheet of paper. X-ray radiographic image was collected at Portland 
Community College by Barb Smith at 90 keV.  
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Figure A.1. Bismuth nanoparticles synthesized in ethylene glycol and surface 
stabilized with glucose. Particles were synthesized at temperatures noted in 
upper left corner. TEM images are representative of morphologies generally 
observed from each synthesis.  
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Figure A.2. Bismuth nanoparticles synthesized in the absence of glucose (A) or 
in water (B). Particles synthesized without glucose were not oxidatively stable in 
water and readily decomposed to a white bismuth oxide precipitate. 
 
 
 
Figure A.3. XRD absorbance profile of bismuth nanoparticles with rounded 
morphologies (115°C) or with pseudocubic morphologies (75 °C). Profiles display 
identical relative peak height reflection, suggesting an absence of preferential 
crystal orientation of dried samples.  
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Figure A.4. Aqueous glucose-capped bismuth nanoparticle inks. Bismuth 
particles were synthesized and used as X-ray opaque ink for illustratrative 
application. SEM images of particles (top row) show no particle self-organization, 
but a high degree of self-adhesion indicated by formation of cracks. Photograph 
(lower left) and X-ray radiograph (lower right) of nanoparticle inks drawn on paper 
illustrate a potential application as flowable, heavy element nanoparticle X-ray 
opaque inks.   
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Appendix B. - Bismuth Nanoparticles Stabilized by a Variety of Reducing 
Sugars, and the pH Dependent Stability of Glucose Capped Particles  
 
 
Bismuth nanoparticles were synthesized and surface stabilized using 
mono- and di- saccharides to assess effects of surface stabilizers on nanocrystal 
morphology. A method, described in detail in Chapter 3 of this document, was 
modified for use of sugars other than glucose. In short, 10 mM Bi(III) nitrate (100 
µmol) and 1 M (0.9-3.42 g) of the specified sugar were heated to 80 °C in 10 mL 
1,2-propane diol. Borane morpholine (310 µMol) suspended in 310 µL 1,2-
propanediol was added and the solution was allowed to react for 20 sec to 5 
minutes before dilution in ice water. The dihydroxyacetone solution reacted for 20 
seconds, the fructose, ribose, and glucose solutions reacted for 60 seconds, and 
the maltose solution reacted for 5 minutes. In the presence of non-reducing 
sugars, namely xylitol, sorbitol, and trehalose, no blackening of reaction solution, 
indicating stabilization of bismuth particles, was observed. Particles were 
collected by centrifugation (4.4 rcf, 20 min) and washed in nanopure water prior 
to analysis. Transmission Electron Microscopy (TEM) was performed on an FEI 
Tecnai F-20 TEM operating at 200 kV. All particles were carried in water and 
dropcast onto holey carbon copper supported grids and dried for at least 2 hours 
at 150°C prior to imaging.   
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Figure A.5. Bismuth nanoparticles synthesized in 1,2-propanediol with various 
reducing sugar surfactants. Chemical structures of surfactants are shown in 
lower right corner. All scale bars represent 50 nm. 
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Figure A.6. pH dependent stability of glucose capped bismuth nanoparticles. 
Particles were mixed into phosphate solutions (1 M) with pH values between 6 
and 12, and photographed at 5 minutes and at 24 hours. Solutions with pH 
values between 8 and 10 appeared coloidally stable for greater than 1 month. 
 
 Glucose capped particles were synthesized as previously described 
(section 3.3). An unknown bismuth concentration of particles was assessed for 
pH stability in 1 molar phosphate buffered solutions ranging in pH from 6 to 12. 
(Figure A.6) Briefly, 100 µL of the nanoparticle solution, in water, was added to 
1 mL of the phosphate solutions. Photographs were taken at 5 minutes, to 
illustrate dispersion, and vials were stored in the dark at room temperature over 
night. Another photograph was taken at 24 hours to illustrate oxidative 
decomposition of the particles in solutions with pH value of 6, 7, 7.5, 11, and 12. 
Particles in solutions with a pH value of 8, 9, and 10 showed no indication of 
oxidative decomposition over night, and remained colloidally stable in solution for 
! 211!
at least 1 month.  As discussed in detail in Chapter 3 of this document, these pH 
dependent stability observations suggests glucose capped particles will be 
oxidatively decomposed when used as an in vivo X-ray contrast material. 
